Nexcella, an Immix Biopharma subsidiary, Announces Positive 58-Patient NXC-201 Clinical Data: 100% Overall Response Rate in Light Chain (AL) Amyloidosis; 92% Overall Response Rate in Multiple Myeloma at the EBMT 49th Annual Meeting in Paris

Multiple Myeloma

  • 92% was the overall response rate produced by NXC-201 in relapsed/refractory multiple myeloma patients treated at the therapeutic dose of 800 million CAR+T cells in its ongoing phase 1b/2a NEXICART-1 clinical trial (NCT04720313) who were not exposed to prior BCMA-targeted therapy, producing a median progression free survival (mPFS) of 12.3 months as of the February 9, 2023 data cutoff
  • The $13.9 billion Multiple Myeloma market in 2017 is expected to reach $28.7 billion in 2027 according to Wilcock, et al. Nature Reviews
  • Nexcella plans to submit a BLA for FDA approval in multiple myeloma once 100 patients are treated with NXC-201
  • The expected primary endpoint for NXC-201 in relapsed/refractory multiple myeloma is overall response rate

AL Amyloidosis

  • 100% (8/8) was the overall response rate produced by NXC-201 in 8 light chain (AL) amyloidosis patients in our ongoing phase 1b/2a NEXICART-1 clinical trial (NCT04720313)
  • The Amyloidosis market was $3.6 billion in 2017, expected to reach $6 billion in 2025, according to Grand View Research
  • The expected primary endpoint for a pivotal study of NXC-201 in relapsed/refractory AL Amyloidosis is overall response rate
  • Nexcella plans to submit a BLA for FDA approval in AL amyloidosis once 30-40 patients are treated with NXC-201


Nexcella Announces Positive 58-Patient NXC-201 Clinical Data: 100% Overall Response Rate in light chain (AL) Amyloidosis; 92% Overall Response Rate in Multiple Myeloma at the EBMT 49



th Annual Meeting in Paris

Nexcella, Inc. a subsidiary of Immix Biopharma, Inc. (NASDAQ:IMMX)



LOS ANGELES, April 26, 2023 (GLOBE NEWSWIRE) — Nexcella Inc., a subsidiary of Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), today announced new positive clinical data from its ongoing Phase 1b/2 NEXICART-1 (NCT04720313) study of its novel, autologous, BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 for the treatment of patients with relapsed or refractory light chain (AL) amyloidosis and multiple myeloma. The dataset represents 8 new evaluable patients in multiple myeloma and 3 new evaluable patients in light chain (AL) amyloidosis (paper and poster publications www.nexcella.com/publications). The new data are being presented during a poster presentation at the European Society for Blood and Marrow Transplantation 49th Annual Meeting in Paris, France, April 23-26.

“We continue to be very encouraged by NXC-201 clinical results,” said Polina Stepensky, M.D., Director of the Hadassah Medical Organization’s Department of Bone Marrow Transplantation and Immunotherapy for Adults and Children, and principal study investigator. “In multiple myeloma, these data are compelling as the overall response rate for ABECMA was 72% in its pivotal KarMMa trial with 100 patients in relapsed or refractory multiple myeloma. In AL Amyloidosis, NXC-201’s very promising response could offer hope to patients who have already been treated with a 4-drug standard-of-care combination incorporating DARZALEX.  In particular, NXC-201 may offer a valuable option for both multiple myeloma and AL amyloidosis patients who have progressed on standards of care.”

As of the February 9, 2023 data cutoff, updated clinical data in 58 patients from the ongoing NEXICART-1 (NCT04720313) study of the novel, autologous, BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 for the treatment of relapsed or refractory multiple myeloma and light chain amyloidosis (AL) was presented. At all doses of NXC-201 across 50 patients, median follow-up was 5.7 months (range: 0.6-17.5 months). NXC-201 clinical data showed:

Multiple Myeloma

  • 92% was the overall response rate produced by NXC-201 in relapsed/refractory multiple myeloma patients treated at the therapeutic dose of 800 million CAR+T cells in its ongoing phase 1b/2a NEXICART-1 clinical trial (NCT04720313) who were not exposed to prior BCMA-targeted therapy, producing a median progression free survival (mPFS) of 12.3 months
  • 87% overall response rate (32 of 37 patients at the therapeutic dose of 800 million CAR+T cells) was observed in NEXICART-1 (NCT04720313) trial in relapsed/refractory multiple myeloma (including both patients with and without prior BCMA-targeted therapy) (Haematologica, 5th European CAR-T cell meeting, 49th EBMT meeting https://www.nexcella.com/publications/)
  • 57% complete response rate (21 out of 37 patients at the therapeutic dose of 800 million CAR+T cells) (including both patients with and without prior BCMA-targeted therapy)
  • The $13.9 billion Multiple Myeloma market in 2017 is expected to reach $28.7 billion in 2027 according to Wilcock, et al. Nature Reviews
  • The expected primary endpoint for NXC-201 in relapsed/refractory multiple myeloma is overall response rate and duration of response
  • Additionally, favorable NXC-201 safety data support investigating NXC-201 as the first potential outpatient CAR-T cell therapy, potentially reducing NXC-201 CAR-T-related hospitalization costs by up to 80%
  • Nexcella plans to submit for FDA approval in multiple myeloma once 100 patients are treated with NXC-201

AL Amyloidosis

  • 100% (8/8) overall response rate, 71% organ response rate (cardiac, renal, liver), 63% complete hematologic response rate (minimum residual disease negativity 10-5), for NXC-201 in 8 relapsed/refractory AL Amyloidosis patients in our ongoing phase 1b/2a NEXICART-1 clinical trial (NCT04720313) (Clinical Cancer Research, 5th European CAR-T cell meeting, 49th EBMT meeting https://www.nexcella.com/publications/)
  • The Amyloidosis market was $3.6 billion in 2017, expected to reach $6 billion in 2025, according to Grand View Research
  • The expected primary endpoint for NXC-201 in relapsed/refractory AL Amyloidosis is overall response rate
  • Nexcella plans to submit for FDA approval in AL amyloidosis once 30-40 patients are treated with NXC-201

“We continue on our path toward 100 patients treated with NXC-201 and a planned BLA submission to the FDA for approval of NXC-201,” said Gabriel Morris, President of Nexcella. “The waiting lists at major academic medical centers in the United States for multiple myeloma CAR-Ts reflect the potential demand for NXC-201.”

“95% of US medical centers cannot offer CAR-T today due to their severe side effect profile,” said Ilya Rachman, M.D., Executive Chairman of Nexcella. “Favorable NXC-201 tolerability could result in not only a 3-day hospital stay instead of the CAR-T standard 14-day hospital stay, but also enable NXC-201 to be delivered in the 95% of US medical centers that cannot offer CAR-Ts today, potentially reducing hospitalization costs by up to 80%.”

The 49th EBMT poster can be accessed on the Nexcella corporate website at this link: https://www.nexcella.com/publications/


Poster Presentation:

Title: “Point-of-care CART manufacture and delivery for the treatment of multiple myeloma and AL amyloidosis: the experience of Hadassah Medical Center”

Event: European Society for Blood and Marrow Transplantation 49th Annual Meeting

Dates: April 23-26, 2023

Location: Palais des Congrès de Paris, 2 Pl. de la Prte Maillot, 75017 Paris, France

Times: Sunday, April 23 08:30 – 19:20 CEST / Monday, April 24 09:00 – 18:00 CEST / Tuesday, April 25 09:00 – 18:00 CEST / Wednesday, April 26 08:30 – 14:15 CEST

The Phase 1b portion of the ongoing Phase 1b/2 clinical trial has been successful in determining the recommended Phase 2 dose (RP2D) of 800 million CAR+T cells. Over the coming months, Nexcella plans to submit an IND application to the FDA for a Phase 1b/2 of NXC-201 in relapsed/refractory multiple myeloma and AL amyloidosis in order to expand the ongoing clinical to the U.S. The expected primary endpoint for the Phase 2 portion of the ongoing Phase 1b/2 clinical trial of NXC-201 in relapsed/refractory multiple myeloma is overall response rate and duration of response. Nexcella plans to submit data to the FDA in multiple myeloma once 100 patients are treated with NXC-201. The expected primary endpoint for NXC-201 in relapsed/refractory AL Amyloidosis is overall response rate. Nexcella plans to submit data to the FDA in AL amyloidosis once 30-40 patients are treated with NXC-201.

About NEXICART-1

NEXICART-1 (NCT04720313) is an ongoing Phase 1b/2, open-label study evaluating the safety and efficacy of NXC-201 (formerly HBI0101), in adults with relapsed or refractory multiple myeloma and AL amyloidosis.
The primary objective of the Phase 1b portion of the study, is to characterize the safety and confirm the Maximally Tolerated Dose (MTD) and Phase 2 dose of NXC-201. The Phase 2 portion of the study will evaluate the efficacy and safety of NXC-201 with endpoints of overall survival, progression-free survival and response rates according to International Myeloma Working Group (IMWG) Uniform Response Criteria.

About NXC-201

NXC-201 (formerly HBI0101) is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and AL amyloidosis.

About Multiple Myeloma

Multiple myeloma (“MM”) is an incurable blood cancer of plasma cells that starts in the bone marrow and is characterized by an excessive proliferation of these cells. Despite initial remission, unfortunately, most patients are likely to relapse. There are 35,730 patients in the United States diagnosed with MM each year. Prognosis for patients who do not respond to or relapse after treatment with standard therapies, including protease inhibitors and immunomodulatory agents remains poor.

About AL Amyloydosis

AL amyloidosis is a rare systemic disorder caused by an abnormality of plasma cells in the bone marrow. Misfolded amyloid proteins produced by plasma cells cause buildup in and around tissues, nerves and organs, gradually affecting their function. This can cause progressive and widespread organ damage, and high mortality rates.

AL amyloidosis affects roughly 30,000 – 40,000 patients in total throughout the U.S. and Europe, and it is estimated that there are approximately 3,000 – 4,000 new cases of AL amyloidosis annually in the U.S. The annual global incidence of AL Amyloidosis is ~15,000 patients. 

About Nexcella, Inc.

Nexcella, Inc., a 98%-owned subsidiary of Immix Biopharma, Inc (NASDAQ:IMMX), is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications. Our N-GENIUS platform allows us to discover, develop, and manufacture cutting-edge cell therapies for patients in need. To learn more about Nexcella, Inc. visit us at www.nexcella.com.

About Immix Biopharma, Inc.

Immix Biopharma, Inc. (ImmixBioTM) (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company pioneering a novel class of Tissue-Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases. Our lead asset is IMX-110, currently in Phase 1b/2a clinical trials as a monotherapy and in its IMMINENT-01 combination clinical trial with BeiGene/Novartis’ anti-PD-1, tisleilizumab, for which patient dosing begin in Feb 2023. IMX-110 holds orphan drug designation (ODD) by the FDA for soft tissue sarcoma, and has received Rare Pediatric Disease Designation (RPDD) by the FDA the treatment of rhabdomyosarcoma, a life-threatening form of cancer in children. RPDD qualifies ImmixBio to receive fast track review and a priority review voucher (PRV) at the time of marketing approval of IMX-110. Additionally, ImmixBio owns 98% of Nexcella, Inc, developing CAR-T NXC-201 for multiple myeloma and AL amyloidosis, with 92% and 100% response rates in each indication, respectively, as of February 9, 2023. Learn more at www.immixbio.com.

Forward Looking Statements

This press release contains “forward-looking statements” Forward-looking statements reflect our current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements, include, but are not limited to, statements contained in this press release relating to our business strategy, our future operating results and liquidity and capital resources outlook. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward–looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, our ability to raise capital to fund continuing operations; our ability to protect our intellectual property rights; the impact of any infringement actions or other litigation brought against us; competition from other providers and products; our ability to develop and commercialize products and services; changes in government regulation; our ability to complete capital raising transactions; and other factors relating to our industry, our operations and results of operations. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned including: the uncertainties related to market conditions and other factors described more fully in the section entitled ‘Risk Factors’ in Immix Biopharma’s Annual Report on Form 10-K for the year ended December 31, 2022, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Immix Biopharma, Inc. specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance or achievements.

Investor Contact:

Suzanne Messere
Stern Investor Relations
[email protected]

Company Contact:


[email protected]

Attachment



Sangamo Therapeutics Announces Strategic Update and Reports Preliminary First Quarter 2023 Financial Results

Sangamo Therapeutics Announces Strategic Update and Reports Preliminary First Quarter 2023 Financial Results

  • Strong clinical momentum continues in Phase 1/2 STAAR study in Fabry disease with 20 patients dosed in total.
  • Dosed third patient in cohort 1 of Phase 1/2 CAR-Treg STEADFAST study for TX200 in HLA A2 mismatched kidney transplantation.
  • Unveiled Nav1.7 target to treat chronic neuropathic pain as flagship program of wholly owned neurology epigenetic regulation pipeline, with IND submission expected in 2024.
  • Announced strategic pipeline prioritization and corporate restructuring, including US workforce reduction of approximately 27%.
  • Conference call and webcast scheduled for Thursday, April 27 at 8:30 a.m. Eastern Time.

BRISBANE, Calif.–(BUSINESS WIRE)–
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced recent business highlights, including a strategic pipeline prioritization and restructuring, and reported certain preliminary first quarter 2023 financial results.

“This quarter, Sangamo continued to advance its clinical and pre-clinical pipeline. Our Phase 1/2 Fabry study continues to enroll and dose patients, alongside preparations for a potential Phase 3 trial expected to commence by the end of 2023. We successfully dosed the third patient with TX200, our CAR-Treg therapy in kidney transplantation, and received positive regulatory feedback from the first two European authorities required to accelerate the dose escalation. We are also excited to unveil Nav 1.7 as the prioritized target in our wholly owned neurology epigenetic regulation pipeline,” said Sandy Macrae, Chief Executive Officer of Sangamo. “Today’s environment necessitates careful choices when deciding how many programs to take forward at once. We are therefore announcing a sharpened strategic focus, prioritizing our investments in our most promising programs. This has led to difficult, but necessary, decisions to step away from certain pre-clinical assets, shrink parts of our infrastructure and redeploy investments towards realizing the full potential of what we believe are our most valuable programs.”

The restructuring announced today is the result of a strategic decision to increase focus on three key areas: Nav 1.7 and Prion as cornerstones to the neurology epigenetic regulation portfolio; Fabry Phase 3 readiness; and the TX200 CAR-Treg clinical study, alongside a broader rightsizing of resources and investments across the company. Additionally, Sangamo expects to significantly reduce its internal manufacturing and allogeneic research footprints in California. As a result of this restructuring, Sangamo is reducing its US workforce by approximately 27%, or approximately 120 roles. These actions are in addition to the previously announced portfolio prioritization which resulted in the decision to seek a partner for our sickle cell disease program. In addition, R. Andrew Ramelmeier, Ph.D., Executive Vice President, Technical Operations will be leaving the company on July 10, 2023. Phillip Ramsey, currently serving as Vice President, Technical Development, has been appointed as Head of Technical Operations effective May 29, 2023.

The restructuring plus other planned cost reduction initiatives are expected to result in annualized savings of approximately $31 million. Sangamo believes its available cash, cash equivalents and marketable securities as of March 31, 2023, in combination with the other expected cost reductions, will be sufficient to fund its planned operations for at least the next 12 months. Sangamo expects to incur approximately $5 million – $7 million in one-time restructuring costs in the second and third quarters of 2023. Sangamo is assessing ways to further reduce annual operating expenses, consistent with the prioritized objectives and progress of the company.

“I am grateful to all our employees for their commitment to Sangamo and dedication to patients, and have special gratitude to those who are leaving for all they have done to advance our mission. Additionally, I would like to personally thank Andy for the passion, dedication and leadership he has brought to Sangamo. He leaves a great legacy of technical excellence and I wish him well in the future.”

Recent Business Highlights

Neurology Epigenetic Regulation Programs – Unveiled Nav1.7 program to treat chronic neuropathic pain as flagship program in prioritized wholly owned neurology pipeline; made strategic decision to pause further development of other pre-clinical programs following conclusion of collaborations with Biogen and Novartis.

  • Announced Nav1.7 to treat chronic neuropathic pain as flagship program in Sangamo’s newly prioritized wholly owned neurology pipeline, with an IND submission expected in 2024. First data from this program expected to be published via a platform presentation at the upcoming American Society for Cell and Gene Therapy (ASGCT) 26th Annual Meeting in Los Angeles in May 2023.

  • Advanced wholly owned prion disease program, with an IND submission anticipated in 2025.

  • Continued to advance identification and selection of engineered AAV capsids for enhanced central nervous system delivery.

  • Following a strategic portfolio evaluation, decided to pause further development of programs previously partnered with Biogen and Novartis, pending the identification of a suitable capsid for delivery for those specific indications.

Fabry disease – Dosed three additional patients in Phase 1/2 STAAR study; advancing Phase 3 trial design planning in anticipation of FDA meeting in the summer; expect to begin pivotal trial by end of 2023.

  • Dosed three additional patients in the dose expansion phase of the Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, our wholly owned gene therapy product for the treatment of Fabry disease, for a total of 20 patients dosed to date. We expect dosing to conclude by the end of 2023.

  • Plan to meet with the FDA on proposed Phase 3 study design in the summer and anticipate commencement of the pivotal trial in the second half of 2023, with dosing of the first patient expected to start as early as the first part of 2024.

Renal Transplant Rejection – Dosed third patient in cohort 1; preparations for higher dose cohort underway; efforts to accelerate dose escalation advancing through regulatory reviews; prioritizing near-term autologous portfolio, resulting in the relocation of allogeneic development and manufacturing activities.

  • Dosed third patient in cohort 1 in the Phase 1/2 STEADFAST study evaluating TX200, our wholly owned autologous CAR-Treg cell therapy treating patients receiving an HLA-A2 mismatched kidney from a living donor.

  • The product candidate continues to be generally well tolerated in all three patients dosed to date.

  • Received positive regulatory feedback for accelerated dose escalation protocol from two European agencies to date.

  • Plan to share initial data from cohort 1 by the end of 2023.

  • Intend to prioritize near-term autologous portfolio, resulting in decision to transition all remaining allogeneic research activities from Sangamo US to Sangamo France, and to cease cell therapy manufacturing in California.

Hemophilia A (Pfizer) – Dosing of patients in Phase 3 AFFINE trial to support primary analysis complete; pivotal data read-out expected in mid-2024; BLA and MAA submissions anticipated in second half of 2024.

  • Dosing of patients to support primary analysis is complete in the Phase 3 AFFINE trial of giroctocogene fitelparvovec, an investigational gene therapy we are developing with Pfizer for patients with moderately severe to severe hemophilia A.

  • A pivotal readout is expected in mid-2024, with Pfizer anticipating BLA and MAA submissions in the second half of 2024.

American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting – 14 Sangamo abstracts accepted.

  • A total of 14 Sangamo abstracts were accepted for presentation at ASGCT on May 16-20, 2023, in Los Angeles, California, including pre-clinical updates from our prioritized neurology programs Nav 1.7 and Prion, innovations in our epigenetic regulation platform and advances in our AAV capsid engineering program.

Preliminary First Quarter 2023 Financial Results

Sangamo is in the process of completing its customary quarter-end close and review procedures, including the evaluation of non-cash charges related to impairment of long-lived assets, as of and for the quarter ended March 31, 2023, and the final results for this period could materially differ from the preliminary expected results disclosed in this press release. Sangamo’s full first quarter 2023 financial results will be reflected in a Quarterly Report on Form 10-Q which is expected to be filed no later than May 10, 2023. The financial performance measures presented in this press release for the first quarter of 2023 are forward-looking statements, preliminary estimates and unaudited, based on management’s initial review of the information presented, and are thus inherently uncertain and subject to change as Sangamo completes its end-of-period reporting process and related activities for the first quarter of 2023. During the course of the review of Sangamo’s condensed consolidated financial statements and related notes as of and for the quarter ended March 31, 2023, Sangamo’s independent registered public accountants may identify items that could cause final reported results to be materially different from the preliminary estimates presented herein. Additional information and disclosures would be required for a more complete understanding of Sangamo’s financial position and results of operations as of and for the quarter ended March 31, 2023. Accordingly, undue reliance should not be placed on this preliminary information.

Revenues

Revenues for the first quarter ended March 31, 2023, are estimated to be approximately $158.0 million, compared to $28.2 million for the same period in 2022.

The estimated increase of $129.8 million in revenues is primarily attributable to an increase of $121.1 million in revenue relating to our collaboration agreement with Biogen, mainly due to the impact of termination related contract modification, and an increase of $6.0 million in revenue relating to our collaboration agreement with Kite, mainly due to a reduction in the estimated project costs, which resulted in an adjustment to the measure of proportional cumulative performance.

Operating Expenses

Total operating expenses on a GAAP basis for the first quarter ended March 31, 2023, are estimated to be in the range of $120 million to $140 million, compared to $73.5 million for the same period in 2022.

The total estimated operating expenses on a GAAP basis for the quarter included certain non-cash charges such as impairment of goodwill of $38.1 million, and impairment of long-lived assets of up to $20 million. These estimated charges are a result of the termination of our collaboration agreements with Biogen and Novartis, a sustained decline in our stock price and related market capitalization and a general decline in equity values in the biotechnology industry.

Cash, Cash Equivalents and Marketable Securities

Cash, cash equivalents and marketable securities as of March 31, 2023 were $241.0 million, compared to $307.5 million as of December 31, 2022.

Sangamo believes its available cash, cash equivalents and marketable securities as of March 31, 2023, in combination with the other expected cost reductions, will be sufficient to fund its planned operations for at least the next 12 months.

Financial Guidance for 2023 Updated

In line with the business announcements outlined, we are revising our full-year operating expense guidance as follows:

  • GAAP operating expenses, including goodwill and long-lived assets impairment charges and stock-based compensation expense, are estimated to be in the range of approximately $315 million to $335 million (updated on April 26, 2023). The previous GAAP operating expenses guidance provided on February 22, 2023 was in the range of approximately $310 million to $330 million.

  • Non-GAAP operating expenses are estimated to be in the range of approximately $240 million to $260 million (updated on April 26, 2023). Estimated non-GAAP operating expenses exclude impairment of goodwill of $38 million, impairment of long-lived assets of up to $20 million and stock-based compensation expense of $35 million. The previous non-GAAP operating expenses guidance provided on February 22, 2023 was in the range of approximately $275 million to $295 million.

Upcoming Events

Sangamo plans to participate in the following events:

Scientific / Medical Conferences

  • ASGCT 26th Annual Meeting, Los Angeles, California, May 16-20, 2023

Investor Conferences

  • 2023 Bank of America Global Healthcare Conference, May 9, 2023

  • 2023 RBC Global Healthcare Conference, May 17, 2023

  • 7th Annual Barclays Gene Editing and Gene Therapy Summit, May 24, 2023

  • Stifel 2023 Tailoring Genes: Genetic Medicines Day, May 30, 2023

  • Jefferies Global Healthcare Conference, June 8, 2023

  • 2023 Wedbush Pacgrow Healthcare Conference, August 8-9, 2023

  • 2023 Wells Fargo Healthcare Conference, September 6-8, 2023

Access links for available webcasts for these investor conferences will be available on the Sangamo website in the Investors and Media section under Events. Available materials will be found on the Sangamo website after the event under Presentations.

Conference Call to Discuss Business Updates and Preliminary First Quarter 2023 Results

The Sangamo management team will discuss these business updates and preliminary results on a conference call tomorrow, Thursday, April 27, 2023, at 8:30 a.m. Eastern Time.

Participants should register for, and access, the call using this link. While not required, it is recommended you join 10 minutes prior to the event start. Once registered, participants will be given the option to either dial into the call with the number and unique passcode provided or to use the dial-out option to connect their phone instantly.

An updated corporate presentation is available in the Investors and Media section under Presentations.

The link to access the live webcast can also be found on the Sangamo website in the Investors and Media section under Events. A replay will be available following the conference call, accessible at the same link.

About Sangamo Therapeutics

Sangamo Therapeutics is a clinical-stage biopharmaceutical company with a robust genomic medicines pipeline. Using ground-breaking science, including our proprietary zinc finger genome engineering technology and manufacturing expertise, Sangamo aims to create new genomic medicines for patients suffering from diseases for which existing treatment options are inadequate or currently don’t exist. To learn more, visit www.sangamo.com and connect with us on LinkedIn and Twitter.

Forward-Looking Statements

This press release contains forward-looking statements regarding our current expectations. These forward-looking statements include, without limitation, statements relating to: our preliminary estimated operating results for the quarter ended March 31, 2023, the therapeutic and commercial potential of our product candidates, the anticipated plans and timelines of Sangamo and our collaborators for screening, enrolling and dosing patients in and conducting our ongoing and potential future clinical trials and presenting clinical data from our clinical trials, including expectations regarding the conclusion of dosing in our Phase 1/2 STAAR study, preparations and plans for patient dosing in the STEADFAST study and the potential for acceleration of the study timeline, the anticipated advancement of our product candidates to late-stage development, including potential future Phase 3 trials of isaralgagene civaparvovec and the timing thereof, the availability and presentation of data from the Phase 3 AFFINE trial, and plans for a BLA and MAA submission for giroctocogene fitelparvovec, expectations regarding advancement of our preclinical neurology programs, including announcement of data from, and anticipated IND submissions related to, such programs, the potential for a partner for our sickle cell disease program; expectations concerning our strategic prioritization and restructuring, including plans to reduce our manufacturing and allogenic research footprints and the expected charges and cost savings associated with such restructuring, future cost reductions, our expected cash runway, our 2023 financial guidance related to GAAP and non-GAAP total operating expenses and stock-based compensation, our plans to participate in industry and investor conferences, and other statements that are not historical fact. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to impediments to adjustments to Sangamo’s preliminary measures of financial performance resulting from, among other things, the completion of Sangamo’s financial close procedures; Sangamo’s ability to execute its strategic prioritization and restructuring as currently contemplated; the actual charges associated with the restructuring being higher than anticipated or changes to the assumptions on which the estimated charges associated with the restructuring are based; Sangamo’s ability to achieve projected cost savings in connection with the restructuring and to further reduce operating expenses; unintended consequences from the restructuring that impact Sangamo’s business; the effects of macroeconomic factors or financial challenges, including as a result of the ongoing conflict between Russia and Ukraine, the COVID-19 pandemic and current or potential future bank failures, on the global business environment, healthcare systems and business and operations of Sangamo and our collaborators, including the initiation and operation of clinical trials; the research and development process, including the enrollment, operation and results of clinical trials and the presentation of clinical data; the impacts of clinical trial delays, pauses and holds on clinical trial timelines and commercialization of product candidates;the uncertain timing and unpredictable nature of clinical trial results, including the risk that therapeutic effects in the Phase 3 AFFINE trial will not be durable in patients as well as the risk that the therapeutic effects observed in the latest preliminary clinical data from the Phase 1/2 STAAR study, including data from kidney biopsies, and the Phase 1/2 PRECIZN-1 study will not be durable in patients and that final clinical trial data from the study will not validate the safety and efficacy of isaralgagene civaparvovec, and that the patients withdrawn from ERT will remain off ERT; the unpredictable regulatory approval process for product candidates across multiple regulatory authorities; reliance on results of early clinical trials, which results are not necessarily predictive of future clinical trial results, including the results of any Phase 3 trial of our product candidates; our limited experience manufacturing biopharmaceutical products, including the risks that we may be unable to maintain compliant manufacturing facilities, build additional facilities and manufacture our product candidates as intended; the potential for technological developments that obviate technologies used by Sangamo;our lack of capital resources to fully develop, obtain regulatory approval for and commercialize our product candidates, and our related need for substantial additional funding to execute our operating plan and to continue to operate as a going concern; our reliance on collaborators and our potential inability to secure additional collaborations, including for our sickle cell disease program; and our ability to achieve expected future financial performance.

There can be no assurance that we and our collaborators will be able to develop commercially viable products. Actual results may differ materially from those projected in these forward-looking statements due to the risks and uncertainties described above and other risks and uncertainties that exist in the operations and business environments of Sangamo and our collaborators. These risks and uncertainties are described more fully in our Securities and Exchange Commission, or SEC, filings and reports, including in our Annual Report on Form 10-K for the year ended December 31, 2022, as supplemented by our Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 to be filed with the SEC, and future filings and reports that Sangamo makes from time to time with the SEC. Forward-looking statements contained in this announcement are made as of this date, and we undertake no duty to update such information except as required under applicable law.

Non-GAAP Financial Measures

To supplement our financial guidance presented in accordance with GAAP, we present non-GAAP total operating expenses financial guidance, which exclude stock-based compensation expense and impairment of goodwill and long-lived assets from GAAP total operating expenses. We believe that these non-GAAP financial measures, when considered together with our financial information prepared in accordance with GAAP, can enhance investors’ and analysts’ ability to meaningfully compare our results from period to period and to our forward-looking guidance, and to identify operating trends in our business. We have excluded stock-based compensation expense because it is a non-cash expense that may vary significantly from period to period as a result of changes not directly or immediately related to the operational performance for the periods presented, and we have excluded impairment of goodwill and long-lived assets to facilitate a more meaningful evaluation of our current operating performance and comparisons to our operating performance in other periods. These non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP financial information, to more fully understand our business.

Investor Relations & Media Inquiries

Louise Wilkie

[email protected]

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Genetics Health

MEDIA:

Logo
Logo

Brookline Bancorp Announces First Quarter Results Reflecting One-Time Costs Associated with PCSB Financial Corporation Acquisition

Net Income of
$7.6 million
, EPS of
$0.09

Operating Earnings of $23.3 million, Operating EPS of $0.27

BOSTON, April 26, 2023 (GLOBE NEWSWIRE) — Brookline Bancorp, Inc. (NASDAQ: BRKL) (the “Company”) today announced net income of $7.6 million, or $0.09 per basic and diluted share, for the first quarter of 2023, compared to net income of $29.7 million, or $0.39 per basic and diluted share, for the fourth quarter of 2022, and net income of $24.7 million, or $0.32 per basic and diluted share, for the first quarter of 2022.

Financial results for the first quarter of 2023 reflect pre-tax one-time costs of $21.5 million associated with the acquisition of PCSB Financial Corporation (“PCSB”) and its subsidiary, PCSB Bank, which closed January 1, 2023. Excluding these one-time costs, operating earnings was $23.3 million, or $0.27 per diluted share, for the first quarter of 2023. These one-time costs consist of merger-related costs of $6.4 million associated with the acquisition and $16.7 million of provision for credit losses expense attributable to the closing of the acquisition, partially offset by $1.7 million in securities gains. Please refer to “Non-GAAP Financial Information” below for a reconciliation of net income to operating earnings.

“I am very pleased to report we successfully completed the acquisition and conversion of PCSB Financial and PCSB Bank,” said Paul Perrault, Brookline Bancorp, Inc. Chairman and Chief Executive Officer. “Our acquisition assures that PCSB Bank will remain well positioned to continue its growth in the New York market. Like all financial institutions, we continue to monitor the recent developments in the banking sector and in our markets, to take advantage of opportunities as they present themselves.”

PCSB FINANCIAL CORPORATION

On January 1, 2023, the Company completed its previously announced acquisition (the “merger”) of PCSB. PCSB’s bank subsidiary, PCSB Bank, now operates as a separate subsidiary of the Company and has 15 banking offices throughout Westchester County and the lower Hudson Valley of New York state. The transaction included the acquisition of approximately $1.3 billion in loans, the assumption of $1.6 billion in deposits, and $52.9 million of borrowings, each at fair value. Total consideration of $297.8 million consisted of 11,820,904 shares of the Company’s common stock issued and cash of $130.5 million.

The following table provides the purchase price allocation of net assets acquired for this transaction:

Assets:  
Cash $ 42,373  
Investments   366,763  
Loans   1,336,737  
Allowance for credit losses on PCD Loans   (2,344 )
Bank premises and equipment   14,631  
Goodwill   80,813  
CDI   30,265  
Other Assets   104,663  
Total Assets Acquired $ 1,973,901  
   
Liabilities:  
Deposits $ 1,570,563  
Borrowings   52,923  
Other Liabilities   52,624  
Total Liabilities $ 1,676,110  
Purchase Price $ 297,791  
       

BALANCE SHEET

Total assets at March 31, 2023 increased $2.3 billion to $11.5 billion from $9.2 billion at December 31, 2022, and increased $2.9 billion from $8.6 billion at March 31, 2022. At March 31, 2023, total loans and leases were $9.2 billion, representing an increase of $1.6 billion from December 31, 2022, and an increase of $2.0 billion from March 31, 2022. The loan portfolio grew $1.6 billion in the first quarter compared to growth of $223.1 million in the fourth quarter.

Total investment securities at March 31, 2023 increased $410.3 million to $1.1 billion from $656.8 million at December 31, 2022, and increased $336.5 million from $730.6 million at March 31, 2022. Total cash and cash equivalents at March 31, 2023 increased $103.3 million to $486.3 million from $383.0 million at December 31, 2022, and increased $193.0 million from $293.3 million at March 31, 2022. As of March 31, 2023, total investment securities and total cash and cash equivalents represented 13.5 percent of total assets as compared to 11.3 percent and 11.9 percent as of December 31, 2022 and March 31, 2022, respectively.

Total deposits at March 31, 2023 increased $1.9 billion to $8.5 billion from $6.5 billion at December 31, 2022, and increased $1.4 billion from $7.1 billion at March 31, 2022.

Total borrowed funds at March 31, 2023 increased $197.5 million to $1.6 billion from $1.4 billion at December 31, 2022, and increased $1.2 billion from $392.9 million at March 31, 2022.

The ratio of stockholders’ equity to total assets was 10.11 percent at March 31, 2023, as compared to 10.80 percent at December 31, 2022, and 11.37 percent at March 31, 2022. The ratio of tangible stockholders’ equity to tangible assets (non-GAAP) was 7.94 percent at March 31, 2023, as compared to 9.20 percent at December 31, 2022, and 9.67 percent at March 31, 2022. Tangible book value per share (non-GAAP) decreased $0.72 from $10.80 at December 31, 2022 to $10.08 at March 31, 2023, compared to $10.56 at March 31, 2022.

NET INTEREST INCOME

Net interest income increased $6.0 million to $86.0 million for the first quarter of 2023 from $80.0 million for the quarter ended December 31, 2022. The net interest margin decreased 45 basis points to 3.36 percent for the three months ended March 31, 2023 from 3.81 percent for the three months ended December 31, 2022.

NON-INTEREST INCOME

Total non-interest income for the quarter ended March 31, 2023 increased $3.9 million to $12.9 million from $9.1 million for the quarter ended December 31, 2022. The increase was primarily driven by increases of $2.1 million in other non-interest income which was primarily driven by the mark to market on interest rate swaps on participated loans and bank owned life insurance income, $1.7 million in loan level derivative income, net, and $1.4 million in gain on securities, net, partially offset by a decrease of $1.0 million in gain on sales of loans and leases and a decrease of $0.3 million in deposit fees.

PROVISION FOR CREDIT LOSSES

The Company recorded a provision for credit losses of $25.5 million for the quarter ended March 31, 2023, compared to $5.7 million for the quarter ended December 31, 2022. The increase in the provision for credit losses was primarily driven by the acquisition of PCSB Bank as well as loan growth.

Total net charge-offs for the first quarter of 2023 were $0.5 million compared to $0.3 million in the fourth quarter of 2022. The increase was primarily driven by an increase in net charge-offs on equipment financing loans of $0.2 million. The ratio of net loan and lease charge-offs to average loans and leases on an annualized basis was 2 basis points for the first quarter of 2023, unchanged from 2 basis points for the fourth quarter of 2022.

The allowance for loan and lease losses represented 1.31 percent of total loans and leases at March 31, 2023, compared to 1.29 percent at December 31, 2022, and 1.32 percent at March 31, 2022.

ASSET QUALITY

The ratio of nonperforming loans and leases to total loans and leases was 0.31 percent at March 31, 2023, an increase from 0.19 percent at December 31, 2022. Total nonaccrual loans and leases increased $13.6 million to $28.5 million at March 31, 2023 from $14.9 million at December 31, 2022. The ratio of nonperforming assets to total assets was 0.25 percent at March 31, 2023, an increase from 0.17 percent at December 31, 2022. Total nonperforming assets increased $13.7 million to $29.0 million at March 31, 2023 from $15.3 million at December 31, 2022. The increase in nonperforming assets was primarily driven by the acquisition of PCSB in addition to a single C&I loan relationship.

NON-INTEREST EXPENSE

Non-interest expense for the quarter ended March 31, 2023 increased $17.6 million to $64.8 million from $47.2 million for the quarter ended December 31, 2022. The increase was primarily driven by increases of $7.0 million in compensation and employee benefits expense, $5.8 million in merger and acquisition expense, $1.8 million in amortization of identified intangible assets expense, $1.2 million in occupancy, $0.7 million in equipment and data processing expense, $0.4 million in advertising and marketing expense, $0.5 million in other non-interest expense, and $0.2 million in FDIC insurance expense, partially offset by a decrease of $0.1 million in professional services expense.

PROVISION FOR INCOME TAXES

The effective tax rate was 12.8 percent for the three months ended March 31, 2023 compared to 17.8 percent for the three months ended December 31, 2022 and 25.2 percent for the three months ended March 31, 2022.

RETURNS ON AVERAGE ASSETS AND AVERAGE EQUITY

The annualized return on average assets decreased to 0.27 percent during the first quarter 2023 from 1.34 percent for the fourth quarter of 2022.

The annualized return on average stockholders’ equity decreased to 2.61 percent during the first quarter of 2023 from 12.09 percent for the fourth quarter of 2022. The annualized return on average tangible stockholders’ equity decreased to 3.43 percent for the first quarter of 2023 from 14.48 percent for the fourth quarter of 2022.

DIVIDEND DECLARED

The Company’s Board of Directors approved a dividend of $0.135 per share for the quarter ended March 31, 2023. The dividend will be paid on May 26, 2023 to stockholders of record on May 12, 2023.

CONFERENCE CALL

The Company will conduct a conference call/webcast at 1:30 PM Eastern Time on Thursday, April 27, 2023 to discuss the results for the quarter, business highlights and outlook. A copy of the Earnings Presentation is available on the Company’s website, www.brooklinebancorp.com. To listen to the call and view the Company’s Earnings Presentation, please join the call via https://events.q4inc.com/attendee/119704415. To listen to the call without access to the slides, interested parties may dial 833-470-1428 (United States) or 404-975-4839 (internationally) and ask for the Brookline Bancorp, Inc. conference call (Access Code 576006). A recorded playback of the call will be available for one week following the call on the Company’s website under “Investor Relations” or by dialing 866-813-9403 (United States) or 204-525-0658 (internationally) and entering the passcode: 989324.

ABOUT BROOKLINE BANCORP, INC.

Brookline Bancorp, Inc., a bank holding company with $11.5 billion in assets and branch locations in Massachusetts, Rhode Island, and the Lower Hudson Valley of New York State, is headquartered in Boston, Massachusetts and operates as the holding company for Brookline Bank, Bank Rhode Island, and PCSB Bank (the “banks”). The Company provides commercial and retail banking services, cash management and investment services to customers throughout Central New England and the Lower Hudson Valley of New York State. More information about Brookline Bancorp, Inc. and its banks can be found at the following websites: www.brooklinebank.com, www.bankri.com and www.pcsb.com.

FORWARD-LOOKING STATEMENTS

Certain statements contained in this press release that are not historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We may also make forward-looking statements in other documents we file with the Securities and Exchange Commission (“SEC”), in our annual reports to shareholders, in press releases and other written materials, and in oral statements made by our officers, directors or employees. You can identify forward looking statements by the use of the words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “assume,” “outlook,” “will,” “should,” and other expressions that predict or indicate future events and trends and which do not relate to historical matters, including statements regarding the Company’s business, credit quality, financial condition, liquidity and results of operations. Forward-looking statements may differ, possibly materially, from what is included in this press release due to factors and future developments that are uncertain and beyond the scope of the Company’s control. These include, but are not limited to, the Company’s ability to achieve the synergies and value creation contemplated by the acquisition of PCSB; turbulence in the capital and debt markets; changes in interest rates; competitive pressures from other financial institutions; general economic conditions (including inflation and concerns about liquidity) on a national basis or in the local markets in which the Company operates; changes in consumer behavior due to changing political, business and economic conditions, or legislative or regulatory initiatives; changes in the value of securities and other assets in the Company’s investment portfolio; increases in loan and lease default and charge-off rates; the adequacy of allowances for loan and lease losses; decreases in deposit levels that necessitate increases in borrowing to fund loans and investments; operational risks including, but not limited to, cybersecurity incidents, fraud, natural disasters, and future pandemics; changes in regulation; the possibility that future credit losses may be higher than currently expected due to changes in economic assumptions and adverse economic developments; the risk that goodwill and intangibles recorded in the Company’s financial statements will become impaired; and changes in assumptions used in making such forward-looking statements. Forward-looking statements involve risks and uncertainties which are difficult to predict. The Company’s actual results could differ materially from those projected in the forward-looking statements as a result of, among others, the risks outlined in the Company’s Annual Report on Form 10-K, as updated by its Quarterly Reports on Form 10-Q and other filings submitted to the SEC. The Company does not undertake any obligation to update any forward-looking statement to reflect circumstances or events that occur after the date the forward-looking statements are made.

BASIS OF PRESENTATION

The Company’s consolidated financial statements have been prepared in conformity with generally accepted accounting principles (“GAAP”) as set forth by the Financial Accounting Standards Board in its Accounting Standards Codification and through the rules and interpretive releases of the SEC under the authority of federal securities laws. Certain amounts previously reported have been reclassified to conform to the current period’s presentation.

NON-GAAP FINANCIAL MEASURES

The Company uses certain non-GAAP financial measures, such as operating earnings, operating earnings per common share, operating return on average assets, operating return on average tangible assets, operating return on average stockholders’ equity, operating return on average tangible stockholders’ equity, tangible book value per common share, tangible stockholders’ equity to tangible assets, return on average tangible assets (annualized) and return on average tangible stockholders’ equity (annualized). These non-GAAP financial measures provide information for investors to effectively analyze financial trends of ongoing business activities, and to enhance comparability with peers across the financial services sector. A detailed reconciliation table of the Company’s GAAP to the non-GAAP measures is attached.

INVESTOR RELATIONS:

Contact: Carl M. Carlson
Brookline Bancorp, Inc.
Co-President and Chief Financial Officer
(617) 425-5331
[email protected]

 
BROOKLINE BANCORP, INC. AND SUBSIDIARIES
Selected Financial Highlights (Unaudited)
                               
  At and for the Three Months Ended


 
  March 31,

2023
  December 31,

2022
  September 30,

2022
  June 30,

2022
  March 31,

2022
  (Dollars In Thousands Except per Share Data)
Earnings Data:                            
Net interest income $ 86,049     $ 80,030     $ 78,026     $ 71,867     $ 69,848  
Provision (credit) for credit losses 25,542     5,725     2,835     227     (160 )
Non-interest income 12,937     9,056     6,834     6,928     5,529  
Non-interest expense 64,776     47,225     44,959     44,871     42,487  
Income before provision for income taxes 8,668     36,136     37,066     33,697     33,050  
Net income 7,560     29,695     30,149     25,195     24,705  
                             
Performance Ratios:                            
Net interest margin (1) 3.36 %   3.81 %   3.80 %   3.56 %   3.49 %
Interest-rate spread (1) 2.66 %   3.35 %   3.58 %   3.41 %   3.31 %
Return on average assets (annualized) 0.27 %   1.34 %   1.40 %   1.18 %   1.16 %
Return on average tangible assets (annualized) (non-GAAP) 0.28 %   1.37 %   1.43 %   1.21 %   1.18 %
Return on average stockholders’ equity (annualized) 2.61 %   12.09 %   12.29 %   10.32 %   9.91 %
Return on average tangible stockholders’ equity (annualized) (non-GAAP) 3.43 %   14.48 %   14.72 %   12.39 %   11.84 %
Efficiency ratio (2) 65.44 %   53.01 %   52.98 %   56.95 %   56.37 %
                             
Per Common Share Data:                            
Net income — Basic $ 0.09     $ 0.39     $ 0.39     $ 0.33     $ 0.32  
Net income — Diluted 0.09     0.39     0.39     0.33     0.32  
Cash dividends declared 0.135     0.135     0.135     0.130     0.130  
Book value per share (end of period) 13.14     12.91     12.54     12.63     12.65  
Tangible book value per share (end of period) (non-GAAP) 10.08     10.80     10.43     10.51     10.56  
Stock price (end of period) 10.50     14.15     11.65     13.31     15.82  
                             
Balance Sheet:                            
Total assets $ 11,522,485     $ 9,185,836     $ 8,695,708     $ 8,514,230     $ 8,633,736  
Total loans and leases 9,246,965     7,644,388     7,421,304     7,291,912     7,223,130  
Total deposits 8,456,462     6,522,146     6,735,605     6,894,457     7,094,378  
Total stockholders’ equity 1,165,066     992,125     963,618     968,496     981,935  
                             
Asset Quality:                            
Nonperforming assets $ 28,962     $ 15,302     $ 18,312     $ 21,259     $ 26,506  
Nonperforming assets as a percentage of total assets 0.25 %   0.17 %   0.21 %   0.25 %   0.31 %
Allowance for loan and lease losses $ 120,865     $ 98,482     $ 94,169     $ 93,188     $ 95,463  
Allowance for loan and lease losses as a percentage of total loans and leases 1.31 %   1.29 %   1.27 %   1.28 %   1.32 %
Net loan and lease charge-offs (recoveries) $ 451     $ 310     $ (179 )   $ 1,242     $ 1,947  
Net loan and lease charge-offs as a percentage of average loans and leases (annualized) 0.02 %   0.02 %   (0.01 )%   0.07 %   0.11 %
                             
Capital Ratios:                            
Stockholders’ equity to total assets 10.11 %   10.80 %   11.08 %   11.38 %   11.37 %
Tangible stockholders’ equity to tangible assets (non-GAAP) 7.94 %   9.20 %   9.39 %   9.65 %   9.67 %
                             
(1) Calculated on a fully tax-equivalent basis.
(2) Calculated as non-interest expense as a percentage of net interest income plus non-interest income.
                             

 
BROOKLINE BANCORP, INC. AND SUBSIDIARIES
Consolidated Balance Sheets (Unaudited)
           
  March 31,
2023
December 31,

2022
September 30,

2022
June 30,

2022
March 31,
2022

ASSETS
(In Thousands Except Share Data)
Cash and due from banks $ 30,782   $ 191,767   $ 65,638   $ 50,429   $ 89,032  
Short-term investments   455,538     191,192     46,873     39,900     204,239  
Total cash and cash equivalents   486,320     382,959     112,511     90,329     293,271  
Investment securities available-for-sale   1,067,032     656,766     675,692     717,818     730,562  
Total investment securities   1,067,032     656,766     675,692     717,818     730,562  
Loans and leases:          
Commercial real estate loans   5,610,414     4,404,148     4,269,512     4,225,754     4,235,325  
Commercial loans and leases   2,147,149     2,016,499     1,933,645     1,860,182     1,800,383  
Consumer loans   1,489,402     1,223,741     1,218,147     1,205,976     1,187,422  
Total loans and leases   9,246,965     7,644,388     7,421,304     7,291,912     7,223,130  
Allowance for loan and lease losses   (120,865 )   (98,482 )   (94,169 )   (93,188 )   (95,463 )
Net loans and leases   9,126,100     7,545,906     7,327,135     7,198,724     7,127,667  
Restricted equity securities   86,230     71,307     44,760     35,406     29,066  
Premises and equipment, net of accumulated depreciation   87,799     71,391     69,912     69,557     69,365  
Right-of-use asset operating leases   30,067     19,484     18,614     18,226     19,571  
Deferred tax asset   75,028     52,237     56,894     50,736     46,886  
Goodwill   241,222     160,427     160,427     160,427     160,427  
Identified intangible assets, net of accumulated amortization   30,080     1,781     1,902     2,022     2,142  
Other real estate owned and repossessed assets   508     408     591     507     990  
Other assets   292,099     223,170     227,270     170,478     153,789  
Total assets $ 11,522,485   $ 9,185,836   $ 8,695,708   $ 8,514,230   $ 8,633,736  

LIABILITIES AND STOCKHOLDERS’ EQUITY
         
Deposits:          
Demand checking accounts $ 1,899,370   $ 1,802,518   $ 1,848,562   $ 1,845,365   $ 1,903,331  
NOW accounts   757,411     544,118     597,870     628,791     627,904  
Savings accounts   1,268,375     762,271     824,789     894,926     967,183  
Money market accounts   2,185,971     2,174,952     2,405,680     2,402,992     2,432,377  
Certificate of deposit accounts   1,362,970     928,143     924,771     1,006,786     1,048,036  
Brokered deposit accounts   982,365     310,144     133,933     115,597     115,547  
Total deposits   8,456,462     6,522,146     6,735,605     6,894,457     7,094,378  
Borrowed funds:          
Advances from the FHLBB   1,458,457     1,237,823     557,895     307,967     201,236  
Subordinated debentures and notes   84,080     84,044     84,008     83,970     83,934  
Other borrowed funds   87,565     110,785     116,865     86,263     107,727  
Total borrowed funds   1,630,102     1,432,652     758,768     478,200     392,897  
Operating lease liabilities   31,373     19,484     18,614     18,226     19,571  
Mortgagors’ escrow accounts   17,080     5,607     5,785     5,771     5,780  
Reserve for unfunded credits   23,112     20,602     19,555     17,511     16,305  
Accrued expenses and other liabilities   199,290     193,220     193,763     131,569     122,870  
Total liabilities   10,357,419     8,193,711     7,732,090     7,545,734     7,651,801  
Stockholders’ equity:          
Common stock, $0.01 par value; 200,000,000 shares authorized; 96,998,075 shares issued, 85,177,172 shares issued, 85,177,172 shares issued, 85,177,172 shares issued, and 85,177,172 shares issued, respectively   970     852     852     852     852  
Additional paid-in capital   904,174     736,074     735,119     738,544     737,658  
Retained earnings, partially restricted   407,528     412,019     392,779     372,677     357,576  
Accumulated other comprehensive income   (52,688 )   (61,947 )   (70,227 )   (44,977 )   (29,322 )
Treasury stock, at cost;          
7,734,891, 7,731,445, 7,730,945, 7,995,888, and 7,037,464 shares, respectively   (94,918 )   (94,873 )   (94,866 )   (98,525 )   (84,718 )
Unallocated common stock held by the Employee Stock Ownership Plan;          
0, 0, 4,833, 11,442, and 18,051 shares, respectively           (39 )   (75 )   (111 )
Total stockholders’ equity   1,165,066     992,125     963,618     968,496     981,935  
Total liabilities and stockholders’ equity $ 11,522,485   $ 9,185,836   $ 8,695,708   $ 8,514,230   $ 8,633,736  
           

 
BROOKLINE BANCORP, INC. AND SUBSIDIARIES
Consolidated Statements of Income (Unaudited)
 
  Three Months Ended
  March 31,

2023
December 31,

2022
September 30,
2022
June 30,

2022
March 31,

2022
  (In Thousands Except Share Data)
Interest and dividend income:          
Loans and leases $ 121,931   $ 98,386   $ 84,375   $ 74,287   $ 71,721  
Debt securities   7,870     3,497     3,337     3,249     2,996  
Restricted equity securities   1,255     766     467     337     328  
Short-term investments   1,495     754     464     156     66  
Total interest and dividend income   132,551     103,403     88,643     78,029     75,111  
Interest expense:          
Deposits   29,368     14,185     7,354     4,282     3,771  
Borrowed funds   17,134     9,188     3,263     1,880     1,492  
Total interest expense   46,502     23,373     10,617     6,162     5,263  
Net interest income   86,049     80,030     78,026     71,867     69,848  
Provision (credit) for credit losses   25,542     5,725     2,835     227     (160 )
Net interest income after provision for credit losses   60,507     74,305     75,191     71,640     70,008  
Non-interest income:          
Deposit fees   2,657     2,916     2,759     2,744     2,500  
Loan fees   391     446     349     666     747  
Loan level derivative income, net   2,373     670     1,275     1,615     686  
Gain on investment securities, net   1,701     321              
Gain on sales of loans and leases held-for-sale   1,638     2,612     889     291     344  
Other   4,177     2,091     1,562     1,612     1,252  
Total non-interest income   12,937     9,056     6,834     6,928     5,529  
Non-interest expense:          
Compensation and employee benefits   36,565     29,525     28,306     28,772     26,884  
Occupancy   5,223     4,005     3,906     3,807     4,284  
Equipment and data processing   6,462     5,758     5,066     4,931     5,078  
Professional services   1,430     1,546     1,069     1,219     1,226  
FDIC insurance   1,244     1,001     709     739     728  
Advertising and marketing   1,410     1,052     1,337     1,319     1,272  
Amortization of identified intangible assets   1,966     120     120     120     134  
Merger and acquisition expense   6,409     641     1,073     535      
Other   4,067     3,577     3,373     3,429     2,881  
Total non-interest expense   64,776     47,225     44,959     44,871     42,487  
Income before provision for income taxes   8,668     36,136     37,066     33,697     33,050  
Provision for income taxes   1,108     6,441     6,917     8,502     8,345  
Net income $ 7,560   $ 29,695   $ 30,149   $ 25,195   $ 24,705  
Earnings per common share:          
Basic $ 0.09   $ 0.39   $ 0.39   $ 0.33   $ 0.32  
Diluted $ 0.09   $ 0.39   $ 0.39   $ 0.33   $ 0.32  
Weighted average common shares outstanding during the period:        
Basic   86,563,641     76,841,655     76,779,038     77,091,013     77,617,227  
Diluted   86,837,806     77,065,076     77,007,971     77,419,288     77,926,822  
Dividends paid per common share $ 0.135   $ 0.135   $ 0.130   $ 0.130   $ 0.125  

 
BROOKLINE BANCORP, INC. AND SUBSIDIARIES
Asset Quality Analysis (Unaudited)
 
  At and for the Three Months Ended
  March 31,

2023
December 31,

2022
September 30,

2022
June 30,

2022
March 31,

2022
  (Dollars in Thousands)
NONPERFORMING ASSETS:                              
Loans and leases accounted for on a nonaccrual basis:                              
Commercial real estate mortgage $ 4,589   $ 607   $ 3,136   $ 6,470   $ 8,313  
Construction   3,883     707              
Total commercial real estate loans   8,472     1,314     3,136     6,470     8,313  
                               
Commercial   5,495     464     618     892     1,366  
Equipment financing   9,908     9,653     10,544     10,183     11,685  
Condominium association   51     58     64     71     77  
Total commercial loans and leases   15,454     10,175     11,226     11,146     13,128  
                               
Residential mortgage   3,449     2,680     2,741     2,412     3,394  
Home equity   1,079     723     616     721     680  
Other consumer       2     2     3     1  
Total consumer loans   4,528     3,405     3,359     3,136     4,075  
                               
Total nonaccrual loans and leases   28,454     14,894     17,721     20,752     25,516  
                               
Other repossessed assets   508     408     591     507     990  
Total nonperforming assets $ 28,962   $ 15,302   $ 18,312   $ 21,259   $ 26,506  
                               
Loans and leases past due greater than 90 days and still accruing $ 726   $ 33   $ 9,583   $ 266   $ 4  
                               
Nonperforming loans and leases as a percentage of total loans and leases   0.31 %   0.19 %   0.24 %   0.28 %   0.35 %
Nonperforming assets as a percentage of total assets   0.25 %   0.17 %   0.21 %   0.25 %   0.31 %
                               
PROVISION AND ALLOWANCE FOR LOAN AND LEASE LOSSES:                              
Allowance for loan and lease losses at beginning of period $ 98,482   $ 94,169   $ 93,188   $ 95,463   $ 99,084  
Charge-offs   (845 )   (658 )   (598 )   (1,533 )   (2,344 )
Recoveries   394     348     777     291     397  
Net (charge-offs) recoveries   (451 )   (310 )   179     (1,242 )   (1,947 )
Provision (credit) for loan and lease losses excluding unfunded commitments *   22,834     4,623     802     (1,033 )   (1,674 )
Allowance for loan and lease losses at end of period $ 120,865   $ 98,482   $ 94,169   $ 93,188   $ 95,463  
                               
Allowance for loan and lease losses as a percentage of total loans and leases   1.31 %   1.29 %   1.27 %   1.28 %   1.32 %
                               
NET CHARGE-OFFS (RECOVERIES):                              
Commercial real estate loans $ (6 ) $ (6 ) $ (6 ) $ (6 ) $ 31  
Commercial loans and leases   457     320     (179 )   1,254     1,948  
Consumer loans       (4 )   6     (6 )   (32 )
Total net charge-offs (recoveries) $ 451   $ 310   $ (179 ) $ 1,242   $ 1,947  
                               
Net loan and lease charge-offs as a percentage of average loans and leases (annualized)   0.02 %   0.02 %   (0.01 )%   0.07 %   0.11 %
           
*Provision for loan and lease losses does not include provision of $2.5 million, $1.0 million, $2.0 million, $1.2 million, and $1.5 million for credit losses on unfunded commitments during the three months ended March 31, 2023, December 31, 2022, September 30, 2022, June 30, 2022 and March 31, 2022, respectively.                                   

 
BROOKLINE BANCORP, INC. AND SUBSIDIARIES
Average Yields / Costs (Unaudited)
 
  Three Months Ended
  March 31, 2023 December 31, 2022 March 31, 2022
  Average
Balance
Interest (1) Average
Yield/Cost
Average
Balance
Interest (1) Average
Yield/Cost
Average
Balance
Interest (1) Average
Yield/Cost
  (Dollars in Thousands)
Assets:                                              
Interest-earning assets:                                              
Investments:                                              
Debt securities (2) $ 1,029,068   $ 7,974 3.10 %   $ 665,969   $ 3,497 2.10 %   $ 720,263   $ 2,996 1.66 %
Marketable and restricted equity securities (2)   76,911     1,255 6.53 %     52,093     766 5.88 %     27,909     328 4.70 %
Short-term investments   147,654     1,495 4.05 %     60,385     754 5.00 %     192,475     66 0.14 %
Total investments   1,253,633     10,724 3.42 %     778,447     5,017 2.58 %     940,647     3,390 1.44 %
Loans and Leases:                                              
Commercial real estate loans (3)   5,579,977     67,667 4.85 %     4,341,929     53,088 4.78 %     4,152,414     36,027 3.47 %
Commercial loans (3)   892,522     14,017 6.28 %     797,312     10,541 5.18 %     755,809     7,998 4.23 %
Equipment financing (3)   1,226,717     21,213 6.92 %     1,200,911     20,816 6.93 %     1,105,194     18,012 6.52 %
Residential mortgage loans (3)   1,032,025     11,073 4.29 %     842,860     8,051 3.82 %     804,939     6,992 3.47 %
Other consumer loans (3)   420,047     7,997 7.71 %     382,196     5,940 6.15 %     366,534     2,750 3.04 %
Total loans and leases   9,151,288     121,967 5.33 %     7,565,208     98,436 5.20 %     7,184,890     71,779 4.00 %
Total interest-earning assets   10,404,921     132,691 5.10 %     8,343,655     103,453 4.96 %     8,125,537     75,169 3.70 %
Non-interest-earning assets   726,166               513,976               405,506          
Total assets $ 11,131,087             $ 8,857,631             $ 8,531,043          
                                               
Liabilities and Stockholders’ Equity:                                              
Interest-bearing liabilities:                                              
Deposits:                                              
NOW accounts $ 810,333     901 0.45 %   $ 583,499     257 0.18 %   $ 589,891     103 0.07 %
Savings accounts   1,160,003     2,514 0.88 %     787,021     1,155 0.58 %     933,173     198 0.09 %
Money market accounts   2,366,235     12,140 2.08 %     2,282,217     7,711 1.34 %     2,416,577     1,570 0.26 %
Certificates of deposit   1,346,761     7,456 2.25 %     922,250     2,865 1.23 %     1,091,729     1,848 0.69 %
Brokered deposit accounts   534,527     6,357 4.82 %     218,188     2,197 3.99 %     132,751     52 0.16 %
Total interest-bearing deposits   6,217,859     29,368 1.92 %     4,793,175     14,185 1.17 %     5,164,121     3,771 0.30 %
Borrowings                                              
Advances from the FHLBB   1,264,523     14,531 4.60 %     736,652     6,979 3.71 %     103,878     187 0.72 %
Subordinated debentures and notes   84,062     1,354 6.44 %     84,025     1,332 6.34 %     83,915     1,244 5.93 %
Other borrowed funds   158,499     1,249 3.20 %     148,195     877 2.35 %     130,080     61 0.19 %
Total borrowings   1,507,084     17,134 4.55 %     968,872     9,188 3.71 %     317,873     1,492 1.88 %
Total interest-bearing liabilities   7,724,943     46,502 2.44 %     5,762,047     23,373 1.61 %     5,481,994     5,263 0.39 %
Non-interest-bearing liabilities:                                              
Demand checking accounts   1,930,162               1,843,780               1,880,039          
Other non-interest-bearing liabilities   316,347               269,498               171,717          
Total liabilities   9,971,452               7,875,325               7,533,750          
Stockholders’ equity   1,159,635               982,306               997,293          
Total liabilities and equity $ 11,131,087             $ 8,857,631             $ 8,531,043          
Net interest income (tax-equivalent basis) /Interest-rate spread (4)         86,189 2.66 %           80,080 3.35 %           69,906 3.31 %
Less adjustment of tax-exempt income         140               50               58    
Net interest income       $ 86,049             $ 80,030             $ 69,848    
Net interest margin (5)           3.36 %             3.81 %             3.49 %
                                               
(1) Tax-exempt income on debt securities, equity securities and revenue bonds included in commercial real estate loans is included on a tax-equivalent basis.
(2) Average balances include unrealized gains (losses) on investment securities. Dividend payments may not be consistent and average yield on equity securities may vary from month to month.
(3) Loans on nonaccrual status are included in the average balances.
(4) Interest rate spread represents the difference between the yield on interest-earning assets and the cost of interest-bearing liabilities.
(5) Net interest margin represents net interest income (tax-equivalent basis) divided by average interest-earning assets on an actual/actual basis.

 
BROOKLINE BANCORP, INC. AND SUBSIDIARIES
Non-GAAP Financial Information (Unaudited)
      At and for the Three Months Ended March 31,
        2023 2022
Reconciliation Table – Non-GAAP Financial Information     (Dollars in Thousands Except Share Data)
         
Reported Pretax Income     $ 8,668   $ 33,050  
Less:          
Security gains       1,701      
Add:          
Day 1 PCSB CECL provision       16,744      
Merger and acquisition expense       6,409      
Operating Pretax Income       $ 30,120   $ 33,050  
Estimated effective tax rate         22.7 %   25.2 %
Estimated taxes         6,837     8,345  
Operating earnings after tax       $ 23,283   $ 24,705  
           
Operating earnings per common share:          
Basic       $ 0.27   $ 0.32  
Diluted       $ 0.27   $ 0.32  
           
Weighted average common shares outstanding during the period:        
Basic         86,563,641     77,617,227  
Diluted         86,837,806     77,926,822  
           
           
Return on average assets *       0.27 %   1.16 %
Less:          
Security gains (after-tax) *       0.05 %   %
Add:          
Day 1 PCSB CECL provision *       0.47 %   %
Merger and acquisition expense (after-tax) *       0.18 %   %
Operating return on average assets *       0.87 %   1.16 %
           
           
Return on average tangible assets *       0.28 %   1.18 %
Less:          
Security gains (after-tax) *       0.05 %   %
Add:          
Day 1 PCSB CECL provision *       0.48 %   %
Merger and acquisition expense (after-tax) *       0.18 %   %
Operating return on average tangible assets *       0.89 %   1.18 %
           
           
Return on average stockholders’ equity *       2.61 %   9.91 %
Less:          
Security gains (after-tax) *       0.45 %   %
Add:          
Day 1 PCSB CECL provision *       4.46 %   %
Merger and acquisition expense (after-tax) *       1.71 %   %
Operating return on average stockholders’ equity *       8.33 %   9.91 %
           
           
Return on average tangible stockholders’ equity *       3.43 %   11.84 %
Less:          
Security gains (after-tax) *       0.60 %   %
Add:          
Day 1 PCSB CECL provision *       5.87 %   %
Merger and acquisition expense (after-tax) *       2.25 %   %
Operating return on average tangible stockholders’ equity *       10.95 %   11.84 %
           
* Ratios at and for the three months ended are annualized.        
           
  At and for the Three Months Ended
  March 31,
2023
December 31,
2022
September 30,
2022
June 30,
2022
March 31,
2022
  (Dollars in Thousands)
           
Net income, as reported $ 7,560   $ 29,695   $ 30,149   $ 25,195   $ 24,705  
           
Average total assets $ 11,131,087   $ 8,857,631   $ 8,586,420   $ 8,515,330   $ 8,531,043  
Less: Average goodwill and average identified intangible assets, net   278,135     162,266     162,387     162,507     162,632  
Average tangible assets $ 10,852,952   $ 8,695,365   $ 8,424,033   $ 8,352,823   $ 8,368,411  
           
Return on average tangible assets (annualized)   0.28 %   1.37 %   1.43 %   1.21 %   1.18 %
           
Average total stockholders’ equity $ 1,159,635   $ 982,306   $ 981,379   $ 976,167   $ 997,293  
Less: Average goodwill and average identified intangible assets, net   278,135     162,266     162,387     162,507     162,632  
Average tangible stockholders’ equity $ 881,500   $ 820,040   $ 818,992   $ 813,660   $ 834,661  
           
Return on average tangible stockholders’ equity (annualized)   3.43 %   14.48 %   14.72 %   12.39 %   11.84 %
           
Total stockholders’ equity $ 1,165,066   $ 992,125   $ 963,618   $ 968,496   $ 981,935  
Less:          
Goodwill   241,222     160,427     160,427     160,427     160,427  
Identified intangible assets, net   30,080     1,781     1,902     2,022     2,142  
Tangible stockholders’ equity $ 893,764   $ 829,917   $ 801,289   $ 806,047   $ 819,366  
           
Total assets $ 11,522,485   $ 9,185,836   $ 8,695,708   $ 8,514,230   $ 8,633,736  
Less:          
Goodwill   241,222     160,427     160,427     160,427     160,427  
Identified intangible assets, net   30,080     1,781     1,902     2,022     2,142  
Tangible assets $ 11,251,183   $ 9,023,628   $ 8,533,379   $ 8,351,781   $ 8,471,167  
           
Tangible stockholders’ equity to tangible assets   7.94 %   9.20 %   9.39 %   9.65 %   9.67 %
           
Tangible stockholders’ equity $ 893,764   $ 829,917   $ 801,289   $ 806,047   $ 819,366  
           
Number of common shares issued   96,998,075     85,177,172     85,177,172     85,177,172     85,177,172  
Less:          
Treasury shares   7,734,891     7,731,445     7,730,945     7,995,888     7,037,464  
Unallocated ESOP shares           4,833     11,442     18,051  
Unvested restricted shares   598,049     601,495     601,995     497,297     500,098  
Number of common shares outstanding   88,665,135     76,844,232     76,839,399     76,672,545     77,621,559  
           
Tangible book value per common share $ 10.08   $ 10.80   $ 10.43   $ 10.51   $ 10.56  

  

PDF available: http://ml.globenewswire.com/Resource/Download/bbc06783-cc3a-44b0-adc8-09afc853bed9



ShoulderUp Technology Acquisition Corp. Announces Stockholder Approval of Extension Amendment to the Amended and Restated Certificate of Incorporation and Investment Management Trust Agreement

Kennesaw, GA , April 26, 2023 (GLOBE NEWSWIRE) — ShoulderUp Technology Acquisition Corp. (“ShoulderUp” or the “Company”) (NYSE: SUAC.U; SUAC; SUAC.WS), a blank check company, also commonly referred to as a special purpose acquisition company, or SPAC, formed for the purpose of entering into a merger, capital stock exchange, asset acquisition, stock purchase reorganization or similar business combination with one or more businesses or entities, today announced that its stockholders approved proposals to amend the Investment Management Trust Agreement dated as of November 2021 and the Company’s Amended and Restated Certificate of Incorporation, each by extending the date by which the Company has to consummate a business combination by six (6) months, from May 19, 2023 to November 19, 2023 (the date which is 24 months from the closing date of ShoulderUp’s initial public offering) (such extension, the “Extension”).

In connection with the vote to approve the proposals, the holders of 25,845,428 shares of the Company’s common stock, par value $0.0001 per share, properly exercised their right to redeem their shares (and did not withdraw their redemption) for cash at a redemption price of approximately $10.43 per share, for an aggregate redemption amount of approximately $269,597,444.79. Following such redemptions, approximately $43,336,948.99 will remain in the trust account and 4,154,572 shares of common stock will remain issued and outstanding.

About ShoulderUp

ShoulderUp is a blank check company, also commonly referred to as a special purpose acquisition company, or SPAC, formed for the purpose of entering into a merger, capital stock exchange, asset acquisition, stock purchase reorganization or similar business combination with one or more businesses or entities.

Additional Information

The Company has filed a Proxy Statement with the SEC in connection with the Meeting to consider and vote upon the Charter Amendment Proposal and the Trust Amendment Proposal, among other matters, and, beginning on or about March 29, 2023, mailed the Proxy Statement and other relevant documents to its stockholders as of the March 23, 2023 record date for the Special Meeting. The Company’s stockholders and other interested persons are advised to read the Proxy Statement and any other relevant documents that have been or will be filed with the SEC in connection with the Company’s solicitation of proxies for the Special Meeting because these documents contain important information about the Company, the Charter Amendment Proposal and Trust Amendment Proposal and related matters. Stockholders may also obtain a free copy of the Proxy Statement, as well as other relevant documents that have been or will be filed with the SEC, without charge, at the SEC’s website located at www.sec.gov or by directing a request to: ShoulderUp Technology Acquisition Corp, 125 Townpark Drive, Suite 300, Kennesaw, GA 30144, (650) 276-7040 or to: Okapi Partners, Attention: Chuck Garske / Christian Jacques, (212) 297-0720, or [email protected]

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements regarding the estimated per share redemption price and related matters, as well as all other statements other than statements of historical fact included in this Form 8-K are forward-looking statements. When used in this Form 8-K, words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions, as they relate to us or our management team, identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, the Company’s management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors detailed in the Company’s filings with the SEC. All subsequent written or oral forward-looking statements attributable to the Company or persons acting on its behalf are qualified in their entirety by this paragraph. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the “Risk Factors” section of the Company’s Annual Report on Form 10-K, subsequent quarterly reports on Form 10-Q and initial public offering prospectus. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

ShoulderUp Contact:

ShoulderUp Technology Acquisition Corp, 125 Townpark Drive, Suite 300, Kennesaw, GA 30144, (650) 276-7040; [email protected]



Worldpay From FIS Opens New Growth Opportunities with United Arab Emirates Expansion

Worldpay From FIS Opens New Growth Opportunities with United Arab Emirates Expansion

Key facts

  • Worldpay from FIS continues to drive global e-commerce with new domestic acquiring capability in the UAE.

  • Expansion is part of business’ plans to expand its merchant acquiring presence in key markets.

JACKSONVILLE, Fla.–(BUSINESS WIRE)–
Continuing to build its footprint as a leading global acquirer, global financial technology leader FIS® (NYSE: FIS) has announced today its Worldpay merchant business will be expanding its payment processing capabilities into the United Arab Emirates (UAE) this year.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230426005030/en/

Worldpay has secured a category II payment services license that allows for card acquiring and disbursements. This new domestic license in the UAE will enable the company to offer its world-class payment services to both local companies with global ambitions, and rapidly growing enterprises looking to expand in the market. This comes on the back of its successful expansion into South Korea in 2022.

Our newest version of The Global Payments Report shows the e-commerce market in the UAE is projected to reach US$43 billion by 2026, with credit cards driving this growth, accounting for 41% of e-commerce transaction value in 2022. This makes it even more important for merchants to select the right payment partner for their business.

“The UAE presents new growth opportunities for global businesses and it’s an exciting time to be entering the market,” said Gabriel de Montessus, Head of Global Enterprise Merchant Solutions, FIS. “Our new domestic acquiring capability in the UAE will ensure seamless integration into the country for global merchants, while local businesses will benefit from our leading geographic footprint, enabling them to expand globally. Our expertise in payments helps us understand how local consumers prefer to pay, as well as the trends that merchants need to get ahead of to optimize their performance as they enter new markets and accelerate global commerce.”

Merchants doing business in the UAE will be able to take advantage of Worldpay’s advanced acquiring capabilities, which will be able to connect them to authorization, clearing and payments settlement, dispute management software and data insights. Merchants will also benefit from a seamless payments experience through a single point of integration—helping to increase acceptance, improve customer experience, and reduce fraud. Supporting this new market is a proof point of Worldpay’s growth strategy to enhance its merchant acquiring presence in additional markets and expand its global capability.

About FIS

FIS is a leading provider of technology solutions for financial institutions and businesses of all sizes and across any industry globally. We enable the movement of commerce by unlocking the financial technology that powers the world’s economy. Our employees are dedicated to advancing the way the world pays, banks and invests through our trusted innovation, system performance and flexible architecture. We help our clients use technology in innovative ways to solve business-critical challenges and deliver superior experiences for their customers. Headquartered in Jacksonville, Florida, FIS is a member of the Fortune 500® and the Standard & Poor’s 500® Index. To learn more, visit www.fisglobal.com. Follow FIS on Facebook, LinkedIn and Twitter (@FISGlobal).

Kim Snider, 904.438.6278

Senior Vice President

FIS Global Marketing and Communications

[email protected]

KEYWORDS: Florida United States United Arab Emirates North America Asia Pacific South Korea Middle East

INDUSTRY KEYWORDS: Technology Mobile/Wireless Payments Finance Security Banking Professional Services Software Data Management

MEDIA:

Logo
Logo

Home BancShares, Inc. Announces Second Quarter Cash Dividend

CONWAY, Ark., April 26, 2023 (GLOBE NEWSWIRE) — Home BancShares, Inc. (NYSE: HOMB), parent company of Centennial Bank, today announced that its Board of Directors has declared a regular $0.18 per share quarterly cash dividend payable June 7, 2023, to shareholders of record May 17, 2023. This cash dividend represents a $0.015 per share, or 9.1%, increase over the $0.165 cash dividend paid during the second quarter of 2022.

“Our strong earnings allow us to continue to pay our quarterly dividend. This dividend represents the 68th consecutive quarterly dividend since the Company went public in 2006,” said John Allison, Chairman.

Home BancShares, Inc. is a bank holding company, headquartered in Conway, Arkansas. Its wholly-owned subsidiary, Centennial Bank, provides a broad range of commercial and retail banking plus related financial services to businesses, real estate developers, investors, individuals and municipalities. Centennial Bank has branch locations in Arkansas, Florida, Texas, South Alabama and New York City. The Company’s common stock is traded through the New York Stock Exchange under the symbol “HOMB.”

FOR MORE INFORMATION CONTACT:
Donna Townsell
Senior Executive Vice President &
Director of Investor Relations
(501) 328-4625



First Interstate BancSystem, Inc. Reports First Quarter Earnings

First Interstate BancSystem, Inc. Reports First Quarter Earnings

BILLINGS, Mont.–(BUSINESS WIRE)–
First Interstate BancSystem, Inc. (NASDAQ: FIBK) today reported financial results for the first quarter of 2023. For the quarter, the Company reported net income of $56.3 million, or $0.54 per share, which compares to net income of $85.8 million, or $0.82 per share, for the fourth quarter of 2022, and a net loss of $33.4 million, or $0.36 per share, for the first quarter of 2022.

Earnings include pre-tax acquisition costs of $3.9 million and $65.2 million for the fourth quarter of 2022 and the first quarter of 2022, respectively, which were related to the acquisition of Great Western Bancorp, Inc. (“Great Western”), the parent company of Great Western Bank (“GWB”), which reduced earnings by $0.03 and $0.57 per common share for the fourth quarter of 2022 and the first quarter of 2022, respectively. The first quarter of 2023 did not include comparable costs.

HIGHLIGHTS

  • Net income of $56.3 million, or $0.54 per share, for the first quarter of 2023, was impacted by an available-for-sale investment securities loss of $23.4 million, as well as a $1.9 million fair value adjustment on loans held for sale, or $0.18 per share.

  • Net interest margin, on a fully taxable equivalent basis, decreased to 3.36% for the first quarter of 2023, a 25 basis point decrease from the fourth quarter of 2022. Excluding income related to purchase accounting accretion, the adjusted net interest margin1, on a fully taxable equivalent basis, decreased to 3.29% for the first quarter of 2023, a 20 basis point decrease from the fourth quarter of 2022.

  • Loans held for investment increased $146.5 million, or an annualized 3.2% during the first quarter of 2023 compared to the fourth quarter of 2022. Commercial loans increased $145.4 million, or an annualized 20%, reflecting a continued focus on relationship lending. Total real estate loans increased $78.4 million, or an annualized 2.4%, as an increase in commercial real estate loans was partially offset by a decrease in construction loans. Loans held for investment to deposit ratio increased to 75.7%, as of March 31, 2023, compared to 72.2% as of December 31, 2022 and 60.3% as of March 31, 2022.

  • Book value per common share was $30.28 as of March 31, 2023, compared to $29.43 as of December 31, 2022, and $31.42 as of March 31, 2022. Tangible book value per common share1 was $18.57 as of March 31, 2023, compared to $17.69 as of December 31, 2022 and $19.78 as of March 31, 2022, driven by an increase in retained earnings and changes in accumulated other comprehensive loss related to unrealized losses on available-for-sale securities.

“Throughout our more than 50-year history, First Interstate has prioritized prudent risk management with respect to all aspects of our operations, and as a result, we have continued to be a source of strength and stability for our clients during this challenging period for the banking industry,” said Kevin P. Riley, President and Chief Executive Officer of First Interstate BancSystem, Inc. “Due to the loyal client base we have built, we have seen exceptional stability in our deposit base since the recent bank failures occurred, and we are seeing net growth in new deposit accounts as clients seek stability in their banking relationship.”

“Our first quarter performance evidenced the strong position of the company as we navigate the current uncertain environment. We are well positioned to effectively manage through a wide range of economic scenarios, with strong levels of capital, ample liquidity, and a flexible balance sheet and therefore are not currently contemplating any changes to our strategic planning for the remainder of the year. While prudent risk management will continue to be our top priority, we believe this is a favorable environment for First Interstate to grow our client base, which will contribute to our continued long-term profitable growth and further increase the value of our franchise,” said Mr. Riley.

_______________________________________

1 Non-GAAP financial measure – see Non-GAAP Financial Measures included herein for a reconciliation to GAAP measures.

DIVIDEND DECLARATION

On April 25, 2023, the Company’s board of directors declared a dividend of $0.47 per common share, payable on May 18, 2023, to common stockholders of record as of May 8, 2023. The dividend equates to a 5.3% annualized yield based on the $35.20 per share average closing price of the Company’s common stock as reported on NASDAQ during the first quarter of 2023.

NET INTEREST INCOME

Net interest income decreased $19.5 million, or 7.5%, to $238.9 million, during the first quarter of 2023, compared to net interest income of $258.4 million during the fourth quarter of 2022, primarily due to an increase in interest expense as a result of a higher cost of interest-bearing deposits, a shift into higher cost deposits from non-interest-bearing deposits, higher levels of short-term borrowings, and a $3.2 million decrease in purchase accounting accretion. Net interest income increased $60.5 million, or 33.9%, during the first quarter of 2023, from $178.4 million during the first quarter of 2022, primarily as a result of the full quarter impact of the GWB acquisition.

  • Interest accretion attributable to the fair valuation of acquired loans from acquisitions contributed to net interest income during the first quarter of 2023, the fourth quarter of 2022, and the first quarter of 2022, in the amounts of $5.2 million, $8.4 million, and $7.6 million respectively.

The net interest margin ratio was 3.36% for the first quarter of 2023 compared to 3.61% reported during the fourth quarter of 2022 and 2.80% during the first quarter of 2022. Excluding interest accretion from the fair value of acquired loans, on a quarter-over-quarter basis, the net interest margin ratio decreased 20 basis points, primarily driven by higher short-term borrowing costs, and higher interest-bearing deposit costs, which was partially offset by loan and investment yield expansion. On the same basis year-over-year, the increase in net interest margin was primarily the result of increased yields on earning assets and a shift in the mix of earning assets from cash to investment securities and loans, partially offset by higher short-term borrowings and higher costs of interest-bearing liabilities.

PROVISION FOR (REDUCTION OF) CREDIT LOSSES

During the first quarter of 2023, the Company recorded a provision for credit losses of $15.2 million, including a provision for unfunded commitments of $1.6 million and provision for investment securities of $1.4 million. The increase to the provision for credit losses was primarily a result of loan growth and modest credit migration. This compares to a provision for credit losses of $14.7 million during the fourth quarter of 2022 and $61.3 million during the first quarter of 2022. The decrease from the first quarter of 2022 was primarily related to elevated expected credit losses resulting from the GWB acquisition during the first quarter of 2022.

For the first quarter of 2023, the allowance for credit losses included net charge-offs of $6.2 million, or an annualized 0.14% of average loans outstanding, compared to net charge-offs of $1.1 million, or an annualized 0.02% of average loans outstanding, for the fourth quarter of 2022, and net charge-offs of $16.7 million, or an annualized 0.47% of average loans outstanding, for the first quarter of 2022.

The Company’s allowance for credit losses as a percentage of period-end loans held for investment increased to 1.24% at March 31, 2023 from 1.22% at December 31, 2022, and decreased from 1.46% at March 31, 2022. Coverage of non-performing loans decreased to 265.1% at March 31, 2023, compared to 335.5% at December 31, 2022 and increased from 203.3% at March 31, 2022.

NON-INTEREST INCOME

For the Quarter Ended

Mar 31,

2023

 

Dec 31,

2022

 

$ Change

% Change

 

Mar 31,

2022

 

$ Change

% Change

(Dollars in millions)

 

 

 

 

Payment services revenues

$

18.7

 

 

$

19.4

 

$

(0.7

)

(3.6

)%

 

$

14.8

 

 

$

3.9

 

26.4

%

Mortgage banking revenues

 

2.3

 

 

 

2.6

 

 

(0.3

)

(11.5

)

 

 

8.4

 

 

 

(6.1

)

(72.6

)

Wealth management revenues

 

9.0

 

 

 

8.4

 

 

0.6

 

7.1

 

 

 

8.1

 

 

 

0.9

 

11.1

 

Service charges on deposit accounts

 

5.2

 

 

 

4.9

 

 

0.3

 

6.1

 

 

 

7.7

 

 

 

(2.5

)

(32.5

)

Other service charges, commissions, and fees

 

2.4

 

 

 

2.9

 

 

(0.5

)

(17.2

)

 

 

4.3

 

 

 

(1.9

)

(44.2

)

Investment securities loss

 

(23.4

)

 

 

 

 

(23.4

)

100.0

 

 

 

(0.1

)

 

 

(23.3

)

NM

 

Other income

 

2.2

 

 

 

3.4

 

 

(1.2

)

(35.3

)

 

 

5.6

 

 

 

(3.4

)

(60.7

)

Total non-interest income

$

16.4

 

 

$

41.6

 

$

(25.2

)

(60.6

)%

 

$

48.8

 

 

$

(32.4

)

(66.4

)%

Non-interest income during the first quarter of 2023 decreased $25.2 million compared to the fourth quarter of 2022. The primary driver of the decrease was the result of the realized loss of $23.4 million on the disposition of available-for-sale investment securities and a reduction of $1.9 million related to the fair value of loans held for sale recognized through other income. The Company sold $853.0 million in carrying value of available-for-sale investment securities, with proceeds to be used to reduce our short-term borrowings early in the second quarter of 2023.

Compared to the first quarter of 2022, non-interest income decreased $32.4 million. The decrease was primarily due to the realized loss of $23.4 million on the disposition of available-for-sale investment securities and a $6.1 million decrease in mortgage banking revenues.

NON-INTEREST EXPENSE

For the Quarter Ended

Mar 31,

2023

 

Dec 31,

2022

 

$ Change

% Change

 

Mar 31,

2022

 

$ Change

% Change

(Dollars in millions)

 

 

 

 

Salaries and wages

$

65.6

 

$

75.4

 

$

(9.8

)

(13.0

)%

 

$

60.0

 

$

5.6

 

9.3

%

Employee benefits

 

22.8

 

 

17.3

 

 

5.5

 

31.8

 

 

 

21.2

 

 

1.6

 

7.5

 

Occupancy and equipment

 

18.4

 

 

17.9

 

 

0.5

 

2.8

 

 

 

15.4

 

 

3.0

 

19.5

 

Other intangible amortization

 

4.0

 

 

4.1

 

 

(0.1

)

(2.4

)

 

 

3.6

 

 

0.4

 

11.1

 

Other expenses

 

54.8

 

 

54.5

 

 

0.3

 

0.6

 

 

 

41.7

 

 

13.1

 

31.4

 

Other real estate owned expense

 

0.2

 

 

2.2

 

 

(2.0

)

(90.9

)

 

 

0.1

 

 

0.1

 

100.0

 

Acquisition related expenses

 

 

 

3.9

 

 

(3.9

)

(100.0

)

 

 

65.2

 

 

(65.2

)

(100.0

)

Total non-interest expense

$

165.8

 

$

175.3

 

$

(9.5

)

(5.4

)%

 

$

207.2

 

$

(41.4

)

(20.0

)%

The Company’s non-interest expense was $165.8 million for the first quarter of 2023, a decrease of $9.5 million from the fourth quarter of 2022. The quarter over quarter decrease was primarily driven by lower incentive compensation, lower acquisition related expenses, and a write down of other real estate owned during the fourth quarter of 2022. These decreases were partially offset by an increase in employee benefits due to the seasonal reset of payroll taxes.

Compared to the first quarter of 2022, non-interest expense decreased by $41.4 million. The decrease is largely due to the acquisition expenses related to the acquisition of GWB in the first quarter of 2022, partially offset by a full quarter of increased expenses reflecting the combined entity.

BALANCE SHEET

Total assets decreased $650.1 million, or 2.0%, to $31,637.7 million as of March 31, 2023, from $32,287.8 million as of December 31, 2022, primarily due to a decrease in investment securities. Total assets decreased $1,524.5 million, or 4.6%, from $33,162.2 million as of March 31, 2022, primarily due to a decrease in cash and cash equivalents as a result of declines in deposits.

Investment securities decreased $972.4 million, or 9.4%, to $9,425.5 million as of March 31, 2023, from $10,397.9 million as of December 31, 2022, and decreased $77.0 million, or 0.8%, from $9,502.5 million as of March 31, 2022. The decrease in the current quarter was the result of the disposition of investment securities with the proceeds primarily to be used to reduce other borrowed funds early in the second quarter of 2023.

The following table presents the composition and comparison of loans held for investment as of the quarters-ended:

 

March 31,

2023

December 31,

2022

$

Change

%

Change

March 31,

2022

$

Change

%

Change

Real estate loans:

 

 

 

 

 

 

 

Commercial

$

8,680.8

 

$

8,528.6

 

$

152.2

 

1.8

%

$

7,805.7

 

$

875.1

 

11.2

%

Construction loans:

 

 

 

 

 

 

 

Land acquisition & development

 

368.5

 

 

386.2

 

 

(17.7

)

(4.6

)

 

344.8

 

 

23.7

 

6.9

 

Residential

 

471.4

 

 

516.2

 

 

(44.8

)

(8.7

)

 

406.0

 

 

65.4

 

16.1

 

Commercial

 

1,053.1

 

 

1,042.0

 

 

11.1

 

1.1

 

 

844.8

 

 

208.3

 

24.7

 

Total construction loans

 

1,893.0

 

 

1,944.4

 

 

(51.4

)

(2.6

)

 

1,595.6

 

 

297.4

 

18.6

 

Residential

 

2,191.1

 

 

2,188.3

 

 

2.8

 

0.1

 

 

1,997.5

 

 

193.6

 

9.7

 

Agricultural

 

769.7

 

 

794.9

 

 

(25.2

)

(3.2

)

 

833.6

 

 

(63.9

)

(7.7

)

Total real estate loans

 

13,534.6

 

 

13,456.2

 

 

78.4

 

0.6

 

 

12,232.4

 

 

1,302.2

 

10.6

 

Consumer loans:

 

 

 

 

 

 

 

Indirect

 

817.3

 

 

829.7

 

 

(12.4

)

(1.5

)

 

739.6

 

 

77.7

 

10.5

 

Direct and advance lines

 

146.9

 

 

152.9

 

 

(6.0

)

(3.9

)

 

142.5

 

 

4.4

 

3.1

 

Credit card

 

71.5

 

 

75.9

 

 

(4.4

)

(5.8

)

 

73.5

 

 

(2.0

)

(2.7

)

Total consumer loans

 

1,035.7

 

 

1,058.5

 

 

(22.8

)

(2.2

)

 

955.6

 

 

80.1

 

8.4

 

Commercial

 

3,028.0

 

 

2,882.6

 

 

145.4

 

5.0

 

 

3,017.9

 

 

10.1

 

0.3

 

Agricultural

 

660.4

 

 

708.3

 

 

(47.9

)

(6.8

)

 

744.3

 

 

(83.9

)

(11.3

)

Other, including overdrafts

 

1.6

 

 

9.2

 

 

(7.6

)

(82.6

)

 

4.6

 

 

(3.0

)

(65.2

)

Deferred loan fees and costs

 

(14.6

)

 

(15.6

)

 

1.0

 

(6.4

)

 

(9.8

)

 

(4.8

)

49.0

 

Loans held for investment, net of deferred loan fees and costs

$

18,245.7

 

$

18,099.2

 

$

146.5

 

0.8

%

$

16,945.0

 

$

1,300.7

 

7.7

%

The ratio of loans held for investment to deposits increased to 75.7%, as of March 31, 2023, compared to 72.2% as of December 31, 2022, and 60.3% as of March 31, 2022.

Total deposits decreased $966.6 million, or 3.9%, to $24,107.0 million as of March 31, 2023, from $25,073.6 million as of December 31, 2022, and decreased $3,981.3 million, or 14.2%, from $28,088.3 million as of March 31, 2022, in all categories with the exception of time deposits.

Securities sold under repurchase agreements decreased $82.1 million, or 7.8%, to $970.8 million as of March 31, 2023, from $1,052.9 million as of December 31, 2022 and decreased $100.2 million, or 9.4%, from $1,071.0 million as of March 31, 2022. The decreases in securities sold under repurchase agreements correspond with fluctuations in the liquidity of the Company’s clients.

Other borrowed funds is comprised of Federal Home Loan Bank variable rate overnight and fixed rate borrowings in tenors up to three-months. Other borrowed funds increased $383.0 million, or 16.5%, to $2,710.0 million as of March 31, 2023, from $2,327.0 million as of December 31, 2022 and increased $2,710.0 million from March 31, 2022.

The Company is considered to be “well-capitalized” as of March 31, 2023, having exceeded all regulatory capital adequacy requirements. During the first quarter of 2023, the Company paid regular common stock dividends of approximately $48.3 million, or $0.47 per share.

CREDIT QUALITY

As of March 31, 2023, non-performing assets increased $20.4 million, or 26.1%, to $98.7 million, compared to $78.3 million as of December 31, 2022, primarily driven by an increase in non-accrual loans of $21.6 million, or 36.5%, and an increase in property classified as other real estate owned of $0.7 million, or 5.5%, partially offset by a decrease in accruing loans past due 90 days or more of $1.9 million.

Criticized loans increased $6.5 million, or 1.1%, to $621.6 million as of March 31, 2023, from $615.1 million as of December 31, 2022.

Net loan charge-offs increased to $6.2 million during the first quarter of 2023 as compared to $1.1 million during the fourth quarter of 2022. The net loan charge-offs in the first quarter of 2023 were composed of charge-offs of $8.9 million and recoveries of $2.7 million.

NON-GAAP FINANCIAL MEASURES

In addition to results presented in accordance with accounting principles generally accepted in the United States of America, or GAAP, this press release contains the following non-GAAP financial measures that management uses to evaluate our performance relative to our capital adequacy standards: (i) tangible common stockholders’ equity; (ii) tangible assets; (iii) tangible book value per common share; (iv) tangible common stockholders’ equity to tangible assets; (v) average tangible common stockholders’ equity; (vi) return on average tangible common stockholders’ equity; and (vii) adjusted net interest margin. Tangible common stockholders’ equity is calculated as total common stockholders’ equity less goodwill and other intangible assets (excluding mortgage servicing rights). Tangible assets are calculated as total assets less goodwill and other intangible assets (excluding mortgage servicing rights). Tangible book value per common share is calculated as tangible common stockholders’ equity divided by common shares outstanding. Tangible common stockholders’ equity to tangible assets is calculated as tangible common stockholders’ equity divided by tangible assets. Average tangible common stockholders’ equity is calculated as average stockholders’ equity less average goodwill and other intangible assets (excluding mortgage servicing rights). Return on average tangible common stockholders’ equity is calculated as net income available to common shareholders divided by average tangible common stockholders’ equity. Adjusted net interest margin ratio (FTE) is calculated as adjusted net FTE interest income divided by adjusted average interest earning assets. These non-GAAP financial measures may not be comparable to similarly titled measures reported by other companies because other companies may not calculate these non-GAAP measures in the same manner. They also should not be considered in isolation or as a substitute for measures prepared in accordance with GAAP.

The Company adjusts the most directly comparable capital adequacy GAAP financial measures to the non-GAAP financial measures described in subclauses (i) through (vi) above to exclude goodwill and other intangible assets (except mortgage servicing rights). To derive the non-GAAP financial measure identified in subclause (vii) above, the Company adjusts its net interest income to include its FTE interest income and exclude purchase accounting interest accretion on acquired loans and PPP loan income, and it adjusts average interest-earning assets to exclude average PPP loan balances. Management believes these non-GAAP financial measures, which are intended to complement the capital ratios defined by banking regulators and to present on a consistent basis our and our acquired companies’ organic continuing operations without regard to acquisition costs and other adjustments that we consider to be unpredictable and dependent on a significant number of factors that are outside our control, are useful to investors in evaluating the Company’s performance because, as a general matter, they either do not represent an actual cash expense and are inconsistent in amount and frequency depending upon the timing and size of our acquisitions (including the size, complexity and/or volume of past acquisitions, which may drive the magnitude of acquisition related costs, but may not be indicative of the size, complexity and/or volume of future acquisitions or related costs), or they cannot be anticipated or estimated in a particular period (in particular as it relates to unexpected recovery amounts). This impacts the ratios that are important to analysts and allows investors to compare certain aspects of the Company’s capitalization to other companies.

See the Non-GAAP Financial Measures table included herein and the textual discussion for a reconciliation of the above described non-GAAP financial measures to their most directly comparable GAAP financial measures.

Cautionary Note Regarding Forward-Looking Statements and Factors that Could Affect Future Results

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Rule 175 promulgated thereunder, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and Rule 3b-6 promulgated thereunder, that involve inherent risks and uncertainties. Any statements about our, Great Western’s or the combined company’s plans, objectives, expectations, strategies, beliefs, or future performance or events constitute forward-looking statements. Such statements are identified by words or phrases such as “believes,” “expects,” “anticipates,” “plans,” “trends,” “objectives,” “continues” or similar expressions, or future or conditional verbs such as “will,” “would,” “should,” “could,” “might,” “may,” or similar expressions. Forward-looking statements involve known and unknown risks, uncertainties, assumptions, estimates and other important factors that change over time and could cause actual results to differ materially from any results, performance or events expressed or implied by such forward-looking statements. Furthermore, the following factors, among others, may cause actual results to differ materially from current expectations in the forward-looking statements, including those set forth in this press release:

  • new, or changes in, governmental regulations or policies;

  • tax legislative initiatives or assessments;

  • more stringent capital requirements, to the extent they may become applicable to us;

  • changes in accounting standards;

  • any failure to comply with applicable laws and regulations, including the Community Reinvestment Act and fair lending laws, the USA PATRIOT ACT, Office of Foreign Asset Control guidelines and requirements, the Bank Secrecy Act, and the related Financial Crimes Enforcement Network and Federal Financial Institutions Examination Council’s guidelines and regulations;

  • lending and deposit risks and risks associated with sector concentrations;

  • a decline in economic conditions that could reduce demand for our products and services and negatively impact the credit quality of loans;

  • loan credit losses exceeding estimates;

  • the soundness of other financial institutions;

  • the ability to meet cash flow needs and availability of financing sources for working capital and other needs;

  • a loss of deposits or a change in product mix that increases the Company’s funding costs;

  • changes in interest rates;

  • changes to United States trade policies, including the imposition of tariffs and retaliatory tariffs;

  • competition from new or existing financial institutions and non-banks;

  • variable interest rates tied to London Interbank Offered Rate that may no longer be available or may become unreliable;

  • cyber-security risks, including “denial-of-service attacks,” “hacking,” and “identity theft” that could result in the disclosure of confidential information;

  • privacy, information security, and data protection laws, rules, and regulations that affect or limit how we collect and use personal information;

  • the potential impairment of our goodwill and other intangible assets;

  • exposure to losses in collateralized loan obligation securities;

  • exposure to losses in investment securities;

  • our reliance on other companies that provide key components of our business infrastructure;

  • events that may tarnish our reputation;

  • the loss of the services of key members of our management team and directors;

  • our ability to attract and retain qualified employees to operate our business;

  • costs associated with repossessed properties, including environmental remediation;

  • the effectiveness of our systems of internal operating controls;

  • our ability to implement new technology-facilitated products and services or be successful in marketing these products and services to our clients;

  • difficulties we may face in combining the operations of acquired entities or assets with our own operations or assessing the effectiveness of businesses in which we make strategic investments or with which we enter into strategic contractual relationships;

  • incurrence of significant costs related to mergers and related integration activities;

  • the volatility in the price and trading volume of our common stock;

  • “anti-takeover” provisions and the regulations, which may make it more difficult for a third party to acquire control of us even in circumstances that could be deemed beneficial to stockholders;

  • changes in our dividend policy or our ability to pay dividends;

  • our common stock not being an insured deposit;

  • the potential dilutive effect of future equity issuances;

  • the subordination of our common stock to our existing and future indebtedness;

  • the ongoing impact of the COVID-19 pandemic and the U.S., state and local government’s response to the pandemic;

  • changes in general economic conditions caused by inflation, recession, acts of terrorism, and outbreak of hostilities, or other international or domestic calamities, including wars or international conflicts with respect to which the United States may or may not be directly involved, unemployment, or other economic and geopolitical factors;

  • the effect of global conditions, earthquakes, volcanoes, tsunamis, floods, fires, drought, and other natural catastrophic events; and

  • the impact of climate change and environmental sustainability matters.

These factors are not necessarily all the factors that could cause our actual results, performance or achievements to differ materially from those expressed in or implied by any of our forward-looking statements. Other unknown or unpredictable factors also could harm our results.

All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth above and included and described in more detail in our periodic reports filed with the Securities and Exchange Commission, or SEC, under the Securities Exchange Act of 1934, as amended, under the caption “Risk Factors.” Interested parties are urged to read in their entirety such risk factors prior to making any investment decision with respect to the Company. Forward-looking statements speak only as of the date they are made and we do not undertake or assume any obligation to update publicly any of these statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable laws. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

First Quarter 2023 Conference Call for Investors

First Interstate BancSystem, Inc. will host a conference call to discuss the results for the first quarter of 2023 at 11 a.m. Eastern Time (9 a.m. Mountain Time) on Thursday, April 27, 2023. The conference call will be accessible by telephone and through the Internet. Participants may join the call by dialing 1-833-470-1428; the access code is 812721. To participate via the Internet, visit www.FIBK.com. The call will be recorded and made available for replay on April 27, 2023, after 1 p.m. Eastern Time (11 a.m. Mountain Time), through May 27, 2023 , prior to 9 a.m. Eastern Time (7 a.m. Mountain Time), by dialing 1-866-813-9403. The replay access code is 723043. The call will also be archived on our website, www.FIBK.com, for one year.

About First Interstate BancSystem, Inc.

First Interstate BancSystem, Inc. is a financial and bank holding company focused on community banking. Incorporated in 1971 and headquartered in Billings, Montana, the Company operates banking offices, including detached drive-up facilities, in communities across Arizona, Colorado, Idaho, Iowa, Kansas, Minnesota, Missouri, Montana, Nebraska, North Dakota, Oregon, South Dakota, Washington, and Wyoming, in addition to offering online and mobile banking services. Through our bank subsidiary, First Interstate Bank, the Company delivers a comprehensive range of banking products and services to individuals, businesses, municipalities, and others throughout the Company’s market areas.

 

FIRST INTERSTATE BANCSYSTEM, INC. AND SUBSIDIARIES

Consolidated Statements of Income

(Unaudited)

 

 

Quarter Ended

 

% Change

 

(In millions, except % and per share data)

Mar 31,

2023

Dec 31,

2022

Sep 30,

2022

Jun 30,

2022

Mar 31,

2022

 

1Q23 vs

4Q22

1Q23 vs

1Q22

 

Net interest income

$

238.9

 

$

258.4

$

266.8

 

$

239.0

 

$

178.4

 

 

(7.5

)%

33.9

%

 

Net interest income on a fully-taxable equivalent (“FTE”) basis

 

240.7

 

 

260.7

 

268.9

 

 

241.1

 

 

180.0

 

 

(7.7

)

33.7

 

 

Provision for (reduction in) credit losses

 

15.2

 

 

14.7

 

8.4

 

 

(1.7

)

 

61.3

 

 

3.4

 

NM

 

 

Non-interest income:

 

 

 

 

 

 

 

 

 

Payment services revenues

 

18.7

 

 

19.4

 

20.4

 

 

19.5

 

 

14.8

 

 

(3.6

)

26.4

 

 

Mortgage banking revenues

 

2.3

 

 

2.6

 

2.7

 

 

5.0

 

 

8.4

 

 

(11.5

)

(72.6

)

 

Wealth management revenues

 

9.0

 

 

8.4

 

8.5

 

 

9.3

 

 

8.1

 

 

7.1

 

11.1

 

 

Service charges on deposit accounts

 

5.2

 

 

4.9

 

5.7

 

 

6.3

 

 

7.7

 

 

6.1

 

(32.5

)

 

Other service charges, commissions, and fees

 

2.4

 

 

2.9

 

4.7

 

 

3.6

 

 

4.3

 

 

(17.2

)

(44.2

)

 

Total fee-based revenues

 

37.6

 

 

38.2

 

42.0

 

 

43.7

 

 

43.3

 

 

(1.6

)

(13.2

)

 

Investment securities loss

 

(23.4

)

 

 

(24.2

)

 

(0.1

)

 

(0.1

)

 

100.0

 

NM

 

 

Other income

 

2.2

 

 

3.4

 

5.1

 

 

6.3

 

 

5.6

 

 

(35.3

)

(60.7

)

 

Total non-interest income

 

16.4

 

 

41.6

 

22.9

 

 

49.9

 

 

48.8

 

 

(60.6

)

(66.4

)

 

Non-interest expense:

 

 

 

 

 

 

 

 

 

Salaries and wages

 

65.6

 

 

75.4

 

71.9

 

 

74.8

 

 

60.0

 

 

(13.0

)

9.3

 

 

Employee benefits

 

22.8

 

 

17.3

 

19.6

 

 

19.4

 

 

21.2

 

 

31.8

 

7.5

 

 

Occupancy and equipment

 

18.4

 

 

17.9

 

17.1

 

 

17.0

 

 

15.4

 

 

2.8

 

19.5

 

 

Other intangible amortization

 

4.0

 

 

4.1

 

4.1

 

 

4.1

 

 

3.6

 

 

(2.4

)

11.1

 

 

Other expenses

 

54.8

 

 

54.5

 

56.5

 

 

49.2

 

 

41.7

 

 

0.6

 

31.4

 

 

Other real estate owned expense

 

0.2

 

 

2.2

 

 

 

 

 

0.1

 

 

(90.9

)

100.0

 

 

Acquisition related expenses

 

 

 

3.9

 

4.0

 

 

45.8

 

 

65.2

 

 

(100.0

)

(100.0

)

 

Total non-interest expense

 

165.8

 

 

175.3

 

173.2

 

 

210.3

 

 

207.2

 

 

(5.4

)

(20.0

)

 

Income (loss) before income tax

 

74.3

 

 

110.0

 

108.1

 

 

80.3

 

 

(41.3

)

 

(32.5

)

(279.9

)

 

Provision for (benefit from) income tax

 

18.0

 

 

24.2

 

22.4

 

 

16.2

 

 

(7.9

)

 

(25.6

)

(327.8

)

 

Net income (loss)

$

56.3

 

$

85.8

$

85.7

 

$

64.1

 

$

(33.4

)

 

(34.4

)%

(268.6

)%

 

 

 

 

 

 

 

 

 

 

 

Weighted-average basic shares outstanding

 

103,738

 

 

104,445

 

106,526

 

 

109,107

 

 

92,855

 

 

(0.7

)%

11.7

%

 

Weighted-average diluted shares outstanding

 

103,819

 

 

104,548

 

106,590

 

 

109,132

 

 

92,855

 

 

(0.7

)

11.8

 

 

Earnings (loss) per share – basic

$

0.54

 

$

0.82

$

0.80

 

$

0.59

 

$

(0.36

)

 

(34.1

)

(250.0

)

 

Earnings (loss) per share – diluted

 

0.54

 

 

0.82

 

0.80

 

 

0.59

 

 

(0.36

)

 

(34.1

)

(250.0

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

NM – not meaningful

 

 

 

 

 

 

 

 

 

 

FIRST INTERSTATE BANCSYSTEM, INC. AND SUBSIDIARIES

Consolidated Balance Sheets

(Unaudited)

 

 

 

 

 

 

% Change

(In millions, except % and per share data)

Mar 31,

2023

Dec 31,

2022

Sep 30,

2022

Jun 30,

2022

Mar 31,

2022

 

1Q23 vs

4Q22

1Q23 vs

1Q22

Assets:

 

 

 

 

 

 

 

 

Cash and due from banks

$

332.9

 

$

349.2

 

$

390.4

 

$

425.3

 

$

387.6

 

 

(4.7

)%

(14.1

)%

Interest-bearing deposits in banks

 

747.7

 

 

521.2

 

 

201.4

 

 

633.9

 

 

3,423.6

 

 

43.5

 

(78.2

)

Federal funds sold

 

0.1

 

 

0.1

 

 

0.1

 

 

0.1

 

 

0.1

 

 

 

 

Cash and cash equivalents

 

1,080.7

 

 

870.5

 

 

591.9

 

 

1,059.3

 

 

3,811.3

 

 

24.1

 

(71.6

)

Securities purchased under agreement to resell

 

 

 

 

 

 

 

202.2

 

 

102.0

 

 

 

 

Investment securities, net

 

9,425.5

 

 

10,397.9

 

 

10,269.1

 

 

10,871.1

 

 

9,502.5

 

 

(9.4

)

(0.8

)

Investment in Federal Home Loan Bank and Federal Reserve Bank stock

 

214.5

 

 

198.6

 

 

131.9

 

 

107.4

 

 

99.7

 

 

8.0

 

115.1

 

Loans held for sale, at fair value

 

80.9

 

 

79.9

 

 

93.6

 

 

127.4

 

 

178.1

 

 

1.3

 

(54.6

)

Loans held for investment

 

18,245.7

 

 

18,099.2

 

 

17,603.5

 

 

17,162.5

 

 

16,945.0

 

 

0.8

 

7.7

 

Allowance for credit losses

 

226.1

 

 

220.1

 

 

213.0

 

 

220.4

 

 

247.2

 

 

2.7

 

(8.5

)

Net loans held for investment

 

18,019.6

 

 

17,879.1

 

 

17,390.5

 

 

16,942.1

 

 

16,697.8

 

 

0.8

 

7.9

 

Goodwill and intangible assets (excluding mortgage servicing rights)

 

1,221.9

 

 

1,225.9

 

 

1,229.0

 

 

1,232.9

 

 

1,275.2

 

 

(0.3

)

(4.2

)

Company owned life insurance

 

499.4

 

 

497.9

 

 

495.6

 

 

492.8

 

 

490.1

 

 

0.3

 

1.9

 

Premises and equipment

 

443.4

 

 

444.7

 

 

445.4

 

 

442.7

 

 

444.4

 

 

(0.3

)

(0.2

)

Other real estate owned

 

13.4

 

 

12.7

 

 

16.4

 

 

16.8

 

 

17.5

 

 

5.5

 

(23.4

)

Mortgage servicing rights

 

30.1

 

 

31.1

 

 

31.8

 

 

32.1

 

 

32.7

 

 

(3.2

)

(8.0

)

Other assets

 

608.3

 

 

649.5

 

 

649.5

 

 

535.0

 

 

510.9

 

 

(6.3

)

19.1

 

Total assets

$

31,637.7

 

$

32,287.8

 

$

31,344.7

 

$

32,061.8

 

$

33,162.2

 

 

(2.0

)%

(4.6

)%

 

 

 

 

 

 

 

 

 

Liabilities and stockholders’ equity:

 

 

 

 

 

 

 

 

Deposits

$

24,107.0

 

$

25,073.6

 

$

25,884.8

 

$

26,863.8

 

$

28,088.3

 

 

(3.9

)%

(14.2

)%

Securities sold under repurchase agreements

 

970.8

 

 

1,052.9

 

 

1,075.6

 

 

1,234.7

 

 

1,071.0

 

 

(7.8

)

(9.4

)

Long-term debt

 

120.8

 

 

120.8

 

 

120.7

 

 

120.4

 

 

120.4

 

 

 

0.3

 

Other borrowed funds

 

2,710.0

 

 

2,327.0

 

 

625.0

 

 

 

 

 

 

16.5

 

100.0

 

Subordinated debentures held by subsidiary trusts

 

163.1

 

 

163.1

 

 

163.1

 

 

163.1

 

 

163.1

 

 

 

 

Other liabilities

 

405.7

 

 

476.6

 

 

470.0

 

 

407.9

 

 

278.3

 

 

(14.9

)

45.8

 

Total liabilities

 

28,477.4

 

 

29,214.0

 

 

28,339.2

 

 

28,789.9

 

 

29,721.1

 

 

(2.5

)

(4.2

)

Stockholders’ equity:

 

 

 

 

 

 

 

 

Common stock

 

2,478.7

 

 

2,478.2

 

 

2,477.4

 

 

2,607.9

 

 

2,668.6

 

 

 

(7.1

)

Retained earnings

 

1,080.7

 

 

1,072.7

 

 

1,035.8

 

 

993.8

 

 

974.5

 

 

0.7

 

10.9

 

Accumulated other comprehensive (loss) income

 

(399.1

)

 

(477.1

)

 

(507.7

)

 

(329.8

)

 

(202.0

)

 

(16.3

)

97.6

 

Total stockholders’ equity

 

3,160.3

 

 

3,073.8

 

 

3,005.5

 

 

3,271.9

 

 

3,441.1

 

 

2.8

 

(8.2

)

Total liabilities and stockholders’ equity

$

31,637.7

 

$

32,287.8

 

$

31,344.7

 

$

32,061.8

 

$

33,162.2

 

 

(2.0

)%

(4.6

)%

 

 

 

 

 

 

 

 

 

Common shares outstanding at period end

 

104,382

 

 

104,442

 

 

104,451

 

 

107,758

 

 

109,503

 

 

(0.1

)%

(4.7

)%

Book value per common share at period end

$

30.28

 

$

29.43

 

$

28.77

 

$

30.36

 

$

31.42

 

 

2.9

 

(3.6

)

Tangible book value per common share at period end**

 

18.57

 

 

17.69

 

 

17.01

 

 

18.92

 

 

19.78

 

 

5.0

 

(6.1

)

 

 

 

 

 

 

 

 

 

**Non-GAAP financial measure – see Non-GAAP Financial Measures included herein for a reconciliation of book value per common share (GAAP) at period end to tangible book value per common share (non-GAAP) at period end.

FIRST INTERSTATE BANCSYSTEM, INC. AND SUBSIDIARIES

Loans and Deposits

(Unaudited)

 

 

 

 

 

 

% Change

(In millions, except %)

Mar 31,

2023

Dec 31,

2022

Sep 30,

2022

Jun 30,

2022

Mar 31,

2022

 

1Q23 vs

4Q22

1Q23 vs

1Q22

 

 

 

 

 

 

 

 

 

Loans:

 

 

 

 

 

 

 

 

Real Estate:

 

 

 

 

 

 

 

 

Commercial real estate

$

8,680.8

 

$

8,528.6

 

$

8,026.9

 

$

7,857.7

 

$

7,805.7

 

 

1.8

%

11.2

%

Construction:

 

 

 

 

 

 

 

 

Land acquisition and development

 

368.5

 

 

386.2

 

 

393.2

 

 

355.7

 

 

344.8

 

 

(4.6

)

6.9

 

Residential

 

471.4

 

 

516.2

 

 

501.4

 

 

444.8

 

 

406.0

 

 

(8.7

)

16.1

 

Commercial

 

1,053.1

 

 

1,042.0

 

 

1,128.4

 

 

959.0

 

 

844.8

 

 

1.1

 

24.7

 

Total construction

 

1,893.0

 

 

1,944.4

 

 

2,023.0

 

 

1,759.5

 

 

1,595.6

 

 

(2.6

)

18.6

 

Residential real estate

 

2,191.1

 

 

2,188.3

 

 

2,127.7

 

 

2,060.4

 

 

1,997.5

 

 

0.1

 

9.7

 

Agricultural real estate

 

769.7

 

 

794.9

 

 

800.9

 

 

821.5

 

 

833.6

 

 

(3.2

)

(7.7

)

Total real estate

 

13,534.6

 

 

13,456.2

 

 

12,978.5

 

 

12,499.1

 

 

12,232.4

 

 

0.6

 

10.6

 

Consumer:

 

 

 

 

 

 

 

 

Indirect

 

817.3

 

 

829.7

 

 

780.8

 

 

733.9

 

 

739.6

 

 

(1.5

)

10.5

 

Direct

 

146.9

 

 

152.9

 

 

155.0

 

 

157.3

 

 

142.5

 

 

(3.9

)

3.1

 

Credit card

 

71.5

 

 

75.9

 

 

74.2

 

 

74.8

 

 

73.5

 

 

(5.8

)

(2.7

)

Total consumer

 

1,035.7

 

 

1,058.5

 

 

1,010.0

 

 

966.0

 

 

955.6

 

 

(2.2

)

8.4

 

Commercial

 

3,028.0

 

 

2,882.6

 

 

2,966.1

 

 

3,036.0

 

 

3,017.9

 

 

5.0

 

0.3

 

Agricultural

 

660.4

 

 

708.3

 

 

658.2

 

 

672.0

 

 

744.3

 

 

(6.8

)

(11.3

)

Other

 

1.6

 

 

9.2

 

 

3.8

 

 

 

 

4.6

 

 

(82.6

)

(65.2

)

Deferred loan fees and costs

 

(14.6

)

 

(15.6

)

 

(13.1

)

 

(10.6

)

 

(9.8

)

 

(6.4

)

49.0

 

Loans held for investment

$

18,245.7

 

$

18,099.2

 

$

17,603.5

 

$

17,162.5

 

$

16,945.0

 

 

0.8

%

7.7

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Deposits:

 

 

 

 

 

 

 

 

Non-interest-bearing

$

6,861.1

 

$

7,560.0

 

$

8,163.3

 

$

8,295.4

 

$

8,240.6

 

 

(9.2

)%

(16.7

)%

Interest-bearing:

 

 

 

 

 

 

 

 

Demand

 

6,714.1

 

 

7,205.9

 

 

7,595.1

 

 

8,133.3

 

 

8,245.0

 

 

(6.8

)

(18.6

)

Savings

 

8,282.9

 

 

8,379.3

 

 

8,497.2

 

 

8,939.4

 

 

10,004.3

 

 

(1.2

)

(17.2

)

Time, $250 and over

 

526.5

 

 

438.0

 

 

319.3

 

 

272.1

 

 

359.8

 

 

20.2

 

46.3

 

Time, other

 

1,722.4

 

 

1,490.4

 

 

1,309.9

 

 

1,223.6

 

 

1,238.6

 

 

15.6

 

39.1

 

Total interest-bearing

 

17,245.9

 

 

17,513.6

 

 

17,721.5

 

 

18,568.4

 

 

19,847.7

 

 

(1.5

)

(13.1

)

Total deposits

$

24,107.0

 

$

25,073.6

 

$

25,884.8

 

$

26,863.8

 

$

28,088.3

 

 

(3.9

)%

(14.2

)%

 

 

 

 

 

 

 

 

 

Total core deposits (1)

$

23,580.5

 

$

24,635.6

 

$

25,565.5

 

$

26,591.7

 

$

27,728.5

 

 

(4.3

)%

(15.0

)%

 

 

 

 

 

 

 

 

 

(1) Core deposits are defined as total deposits less time deposits, $250 and over, and brokered deposits.

FIRST INTERSTATE BANCSYSTEM, INC. AND SUBSIDIARIES

Credit Quality

(Unaudited)

 

 

 

 

 

 

% Change

(In millions, except %)

Mar 31,

2023

Dec 31,

2022

Sep 30,

2022

Jun 30,

2022

Mar 31,

2022

 

1Q23 vs

4Q22

1Q23 vs

1Q22

 

 

 

 

 

 

 

 

 

Allowance for Credit Losses:

 

 

 

 

 

 

 

 

Allowance for credit losses

$

226.1

 

$

220.1

 

$

213.0

 

$

220.4

 

$

247.2

 

 

2.7

%

(8.5

)%

As a percentage of loans held for investment

 

1.24

%

 

1.22

%

 

1.21

%

 

1.28

%

 

1.46

%

 

 

 

As a percentage of non-accrual loans

 

279.83

 

 

371.79

 

 

268.26

 

 

205.98

 

 

207.91

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loan charge-offs during quarter

$

6.2

 

$

1.1

 

$

12.0

 

$

0.3

 

$

16.7

 

 

NM

 

(62.9

)%

Annualized as a percentage of average loans

 

0.14

%

 

0.02

%

 

0.27

%

 

0.01

%

 

0.47

%

 

 

 

 

 

 

 

 

 

 

 

 

Non-Performing Assets:

 

 

 

 

 

 

 

 

Non-accrual loans

$

80.8

 

$

59.2

 

$

79.4

 

$

107.0

 

$

118.9

 

 

36.5

%

(32.0

)%

Accruing loans past due 90 days or more

 

4.5

 

 

6.4

 

 

6.6

 

 

2.9

 

 

2.7

 

 

(29.7

)

66.7

 

Total non-performing loans

 

85.3

 

 

65.6

 

 

86.0

 

 

109.9

 

 

121.6

 

 

30.0

 

(29.9

)

Other real estate owned

 

13.4

 

 

12.7

 

 

16.4

 

 

16.8

 

 

17.5

 

 

5.5

 

(23.4

)

Total non-performing assets

$

98.7

 

$

78.3

 

$

102.4

 

$

126.7

 

$

139.1

 

 

26.1

%

(29.0

)%

 

 

 

 

 

 

 

 

 

Non-performing assets as a percentage of:

 

 

 

 

 

 

 

 

Loans held for investment and OREO

 

0.54

%

 

0.43

%

 

0.58

%

 

0.74

%

 

0.82

%

 

 

 

Total assets

 

0.31

 

 

0.24

 

 

0.33

 

 

0.40

 

 

0.42

 

 

 

 

 

 

 

 

 

 

 

 

 

Non-accrual loans to loans held for investment

 

0.44

 

 

0.33

 

 

0.45

 

 

0.62

 

 

0.70

 

 

 

 

 

 

 

 

 

 

 

 

 

Accruing Loans 30-89 Days Past Due

$

52.3

 

$

62.3

 

$

52.5

 

$

56.4

 

$

54.4

 

 

(16.1

)%

(3.9

)%

 

 

 

 

 

 

 

 

 

Criticized Loans:

 

 

 

 

 

 

 

 

Special Mention

$

243.8

 

$

290.4

 

$

273.7

 

$

275.9

 

$

274.6

 

 

(16.0

)%

(11.2

)%

Substandard

 

355.0

 

 

316.2

 

 

277.7

 

 

461.4

 

 

553.9

 

 

12.3

 

(35.9

)

Doubtful

 

22.8

 

 

8.5

 

 

25.5

 

 

42.7

 

 

24.6

 

 

168.2

 

(7.3

)

Total

$

621.6

 

$

615.1

 

$

576.9

 

$

780.0

 

$

853.1

 

 

1.1

%

(27.1

)%

 

 

 

 

 

 

 

 

 

 

NM – not meaningful

FIRST INTERSTATE BANCSYSTEM, INC. AND SUBSIDIARIES

Selected Ratios – Annualized

(Unaudited)

 

 

 

 

 

 

 

 

 

Mar 31,

2023

 

Dec 31,

2022

 

Sep 30,

2022

 

Jun 30,

2022

 

Mar 31,

2022

 

Annualized Financial Ratios (GAAP)

 

Return on average assets

 

0.71

%

 

 

1.07

%

 

 

1.07

%

 

 

0.79

%

 

 

(0.48

)%

 

Return on average common stockholders’ equity

 

7.25

 

 

 

11.16

 

 

 

10.49

 

 

 

7.52

 

 

 

(4.44

)

 

Yield on average earning assets

 

4.43

 

 

 

4.24

 

 

 

3.99

 

 

 

3.35

 

 

 

2.89

 

 

Cost of average interest-bearing liabilities

 

1.46

 

 

 

0.89

 

 

 

0.40

 

 

 

0.14

 

 

 

0.14

 

 

Interest rate spread

 

2.97

 

 

 

3.35

 

 

 

3.59

 

 

 

3.21

 

 

 

2.75

 

 

Net interest margin ratio

 

3.36

 

 

 

3.61

 

 

 

3.71

 

 

 

3.25

 

 

 

2.80

 

 

Efficiency ratio

 

63.38

 

 

 

57.07

 

 

 

58.37

 

 

 

71.37

 

 

 

89.61

 

 

Loans held for investment to deposit ratio

 

75.69

 

 

 

72.18

 

 

 

68.01

 

 

 

63.89

 

 

 

60.33

 

 

 

 

 

 

 

 

 

 

 

 

 

Annualized Financial Ratios – Operating** (Non-GAAP)

 

Tangible book value per common share

$

18.57

 

 

$

17.69

 

 

$

17.01

 

 

$

18.92

 

 

$

19.78

 

 

Tangible common stockholders’ equity to tangible assets

 

6.37

%

 

 

5.95

%

 

 

5.90

%

 

 

6.61

%

 

 

6.79

%

 

Return on average tangible common stockholders’ equity

 

11.87

 

 

 

18.67

 

 

 

16.93

 

 

 

11.78

 

 

 

(6.88

)

 

 

 

 

 

 

 

 

 

 

 

 

Consolidated Capital Ratios

 

Total risk-based capital to total risk-weighted assets

 

12.63

%

*

 

12.48

%

 

 

12.50

%

 

 

13.16

%

 

 

13.79

%

 

Tier 1 risk-based capital to total risk-weighted assets

 

10.52

 

*

 

10.45

 

 

 

10.49

 

 

 

11.09

 

 

 

11.52

 

 

Tier 1 common capital to total risk-weighted assets

 

10.52

 

*

 

10.45

 

 

 

10.49

 

 

 

11.09

 

 

 

11.52

 

 

Leverage Ratio

 

7.72

 

*

 

7.75

 

 

 

7.67

 

 

 

7.72

 

 

 

8.96

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

*Preliminary estimate – may be subject to change. The regulatory capital ratios presented include the assumption of the transitional method as a result of legislation by the U.S. Congress to provide relief for the economy and financial institutions in the United States from the COVID‑19 pandemic. The referenced relief ends on December 31, 2024 which allows a total five-year phase-in of the impact of CECL on capital and relief over the next two years for the impact on the allowance for credit losses resulting from the COVID‑19 pandemic.

 

**Non-GAAP financial measures – see Non-GAAP Financial Measures included herein for a reconciliation of book value per common share to tangible book value per common share, return on average common stockholders’ equity (GAAP) to return on average tangible common stockholders’ equity, and tangible common stockholders’ equity to tangible assets (non-GAAP).

 

 

 

FIRST INTERSTATE BANCSYSTEM, INC. AND SUBSIDIARIES

Average Balance Sheets

(Unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

March 31, 2023

 

December 31, 2022

 

March 31, 2022

(In millions, except %)

Average

Balance

Interest

Average

Rate

 

Average

Balance

Interest

Average

Rate

 

Average

Balance

Interest

Average

Rate

Interest-earning assets:

 

 

 

 

 

 

 

 

 

 

 

Loans (1) (2)

$

18,273.6

$

237.2

 

5.26

%

 

$

17,920.5

$

230.5

 

5.10

%

 

$

14,460.6

$

153.0

 

4.29

%

Investment securities (2)

 

10,208.8

 

73.3

 

2.91

 

 

 

10,383.8

 

71.6

 

2.74

 

 

 

8,279.3

 

30.9

 

1.51

 

Investment in FHLB and FRB stock

 

210.5

 

3.0

 

5.78

 

 

 

156.4

 

2.0

 

5.07

 

 

 

83.6

 

0.4

 

1.94

 

Interest-bearing deposits in banks

 

365.7

 

4.2

 

4.66

 

 

 

220.1

 

2.2

 

3.97

 

 

 

3,263.1

 

1.7

 

0.21

 

Federal funds sold

 

0.8

 

 

 

 

 

0.1

 

 

 

 

 

0.1

 

 

 

Total interest-earning assets

$

29,059.4

$

317.7

 

4.43

%

 

$

28,680.9

$

306.3

 

4.24

%

 

$

26,086.7

$

186.0

 

2.89

%

Non-earning assets

 

2,951.5

 

 

 

 

3,035.1

 

 

 

 

2,408.4

 

 

Total assets

$

32,010.9

 

 

 

$

31,716.0

 

 

 

$

28,495.1

 

 

Interest-bearing liabilities:

 

 

 

 

 

 

 

 

 

 

 

Demand deposits

$

6,973.4

$

8.7

 

0.51

%

 

$

7,412.7

$

7.9

 

0.42

%

 

$

6,901.8

$

0.9

 

0.05

%

Savings deposits

 

8,406.9

 

22.8

 

1.10

 

 

 

8,446.7

 

14.8

 

0.70

 

 

 

8,332.7

 

1.1

 

0.05

 

Time deposits

 

2,055.3

 

8.8

 

1.74

 

 

 

1,848.6

 

5.0

 

1.07

 

 

 

1,397.2

 

1.0

 

0.29

 

Repurchase agreements

 

1,005.8

 

1.1

 

0.44

 

 

 

1,091.2

 

1.1

 

0.40

 

 

 

1,077.0

 

0.3

 

0.11

 

Other borrowed funds

 

2,615.2

 

31.2

 

4.84

 

 

 

1,260.0

 

12.9

 

4.06

 

 

 

 

 

 

Long-term debt

 

120.8

 

1.5

 

5.04

 

 

 

120.8

 

1.4

 

4.60

 

 

 

127.5

 

1.7

 

5.41

 

Subordinated debentures held by subsidiary trusts

 

163.1

 

2.9

 

7.21

 

 

 

163.1

 

2.5

 

6.08

 

 

 

136.9

 

1.0

 

2.96

 

Total interest-bearing liabilities

$

21,340.5

$

77.0

 

1.46

%

 

$

20,343.1

$

45.6

 

0.89

%

 

$

17,973.1

$

6.0

 

0.14

%

Non-interest-bearing deposits

 

7,064.9

 

 

 

 

7,871.8

 

 

 

 

7,211.4

 

 

Other non-interest-bearing liabilities

 

458.5

 

 

 

 

451.0

 

 

 

 

260.5

 

 

Stockholders’ equity

 

3,147.0

 

 

 

 

3,050.1

 

 

 

 

3,050.1

 

 

Total liabilities and stockholders’ equity

$

32,010.9

 

 

 

$

31,716.0

 

 

 

$

28,495.1

 

 

Net FTE interest income

 

$

240.7

 

 

 

 

$

260.7

 

 

 

 

$

180.0

 

 

Less FTE adjustments (2)

 

 

(1.8

)

 

 

 

 

(2.3

)

 

 

 

 

(1.6

)

 

Net interest income from consolidated statements of income

 

$

238.9

 

 

 

 

$

258.4

 

 

 

 

$

178.4

 

 

Interest rate spread

 

 

2.97

%

 

 

 

3.35

%

 

 

 

2.75

%

Net FTE interest margin (3)

 

 

3.36

 

 

 

 

3.61

 

 

 

 

2.80

 

Cost of funds, including non-interest-bearing demand deposits (4)

 

 

1.10

 

 

 

 

0.64

 

 

 

 

0.10

 

 

 

 

 

 

 

 

 

 

 

 

 

(1) Average loan balances include loans held for sale and non-accrual loans. Interest income on loans includes amortization of deferred loan fees net of deferred loan costs of $0.9 million, $1.2 million, and $3.5 million at March 31, 2023, December 31, 2022, and March 31, 2022, respectively.

(2) Management believes fully taxable equivalent, or FTE, interest income is useful to investors in evaluating the Company’s performance as a comparison of the returns between a tax-free investment and a taxable alternative. The Company adjusts interest income and average rates for tax exempt loans and securities to a FTE basis utilizing a 21.00% and 26.25% tax rate for 2023 and 2022, respectively.

(3) Net FTE interest margin during the period equals (i) the difference between annualized interest income on interest-earning assets and the annualized interest expense on interest-bearing liabilities, divided by (ii) average interest-earning assets for the period.

(4) Calculated by dividing total annualized interest on interest-bearing liabilities by the sum of total interest-bearing liabilities plus non-interest-bearing deposits.

FIRST INTERSTATE BANCSYSTEM, INC. AND SUBSIDIARIES

Non-GAAP Financial Measures

(Unaudited)

 

 

 

 

 

 

 

 

 

As of or For the Quarter Ended

(In millions, except % and per share data)

 

Mar 31, 2023

Dec 31, 2022

Sep 30, 2022

Jun 30, 2022

Mar 31, 2022

Total common stockholders’ equity (GAAP)

(A)

$

3,160.3

 

$

3,073.8

 

$

3,005.5

 

$

3,271.9

 

$

3,441.1

 

Less goodwill and other intangible assets (excluding mortgage servicing rights)

 

 

1,221.9

 

 

1,225.9

 

 

1,229.0

 

 

1,232.9

 

 

1,275.2

 

Tangible common stockholders’ equity (Non-GAAP)

(B)

$

1,938.4

 

$

1,847.9

 

$

1,776.5

 

$

2,039.0

 

$

2,165.9

 

 

 

 

 

 

 

 

Total assets (GAAP)

 

$

31,637.7

 

$

32,287.8

 

$

31,344.7

 

$

32,061.8

 

$

33,162.2

 

Less goodwill and other intangible assets (excluding mortgage servicing rights)

 

 

1,221.9

 

 

1,225.9

 

 

1,229.0

 

 

1,232.9

 

 

1,275.2

 

Tangible assets (Non-GAAP)

(C)

$

30,415.8

 

$

31,061.9

 

$

30,115.7

 

$

30,828.9

 

$

31,887.0

 

 

 

 

 

 

 

 

Average Balances:

 

 

 

 

 

 

Total common stockholders’ equity (GAAP)

(D)

$

3,147.0

 

$

3,050.1

 

$

3,239.7

 

$

3,417.4

 

$

3,050.1

 

Less goodwill and other intangible assets (excluding mortgage servicing rights)

 

 

1,223.8

 

 

1,226.9

 

 

1,230.9

 

 

1,235.1

 

 

1,081.2

 

Average tangible common stockholders’ equity (Non-GAAP)

(E)

$

1,923.2

 

$

1,823.2

 

$

2,008.8

 

$

2,182.3

 

$

1,968.9

 

 

 

 

 

 

 

 

Net interest income

 

$

238.9

 

$

258.4

 

$

266.8

 

$

239.0

 

$

178.4

 

FTE interest income

 

 

1.8

 

 

2.3

 

 

2.1

 

 

2.1

 

 

1.6

 

Net FTE interest income

(F)

 

240.7

 

 

260.7

 

 

268.9

 

 

241.1

 

 

180.0

 

Less purchase accounting accretion

 

 

5.2

 

 

8.4

 

 

17.7

 

 

16.7

 

 

7.6

 

Less PPP income

 

 

 

 

 

 

0.3

 

 

1.1

 

 

2.8

 

Adjusted net FTE interest income

(G)

$

235.5

 

$

252.3

 

$

250.9

 

$

223.3

 

$

169.6

 

 

 

 

 

 

 

 

Average interest-earning assets

(H)

$

29,059.4

 

$

28,680.9

 

$

28,731.2

 

$

29,752.4

 

$

26,086.7

 

Less average PPP loans

 

 

3.8

 

 

5.6

 

 

8.1

 

 

30.8

 

 

91.6

 

Adjusted average earning assets

(I)

$

29,055.6

 

$

28,675.3

 

$

28,723.1

 

$

29,721.6

 

$

25,995.1

 

 

 

 

 

 

 

 

Total quarterly average assets

(J)

$

32,010.9

 

$

31,716.0

 

$

31,653.7

 

$

32,611.3

 

$

28,495.1

 

Annualized net income available to common shareholders

(K)

 

228.3

 

 

340.4

 

 

340.0

 

 

257.1

 

 

(135.5

)

Common shares outstanding

(L)

 

104,382

 

 

104,442

 

 

104,451

 

 

107,758

 

 

109,503

 

Return on average assets (GAAP)

(K) / (J)

 

0.71

%

 

1.07

%

 

1.07

%

 

0.79

%

 

(0.48

)%

Return on average common stockholders’ equity (GAAP)

(K) / (D)

 

7.25

 

 

11.16

 

 

10.49

 

 

7.52

 

 

(4.44

)

Average common stockholders’ equity to average assets (GAAP)

(D) / (J)

 

9.83

 

 

9.62

 

 

10.23

 

 

10.48

 

 

10.70

 

Book value per common share (GAAP)

(A) / (L)

$

30.28

 

$

29.43

 

$

28.77

 

$

30.36

 

$

31.42

 

Tangible book value per common share (Non-GAAP)

(B) / (L)

 

18.57

 

 

17.69

 

 

17.01

 

 

18.92

 

 

19.78

 

Tangible common stockholders’ equity to tangible assets (Non-GAAP)

(B) / (C)

 

6.37

%

 

5.95

%

 

5.90

%

 

6.61

%

 

6.79

%

Return on average tangible common stockholders’ equity (Non-GAAP)

(K) / (E)

 

11.87

 

 

18.67

 

 

16.93

 

 

11.78

 

 

(6.88

)

Net interest margin ratio (FTE) (Non-GAAP)

(F*) / (H)

 

3.36

 

 

3.61

 

 

3.71

 

 

3.25

 

 

2.80

 

Adjusted net interest margin ratio (FTE) (Non-GAAP)

(G*) / (I)

 

3.29

 

 

3.49

 

 

3.47

 

 

3.01

 

 

2.65

 

 

 

 

 

 

 

 

*Annualized

(FIBK-ER)

John R. Stewart, CFA

Deputy Chief Financial Officer

First Interstate BancSystem, Inc.

(406) 255-5311

[email protected]

www.FIBK.com

KEYWORDS: Montana United States North America

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Logo
Logo

BNY Mellon High Yield Strategies Fund Declares Dividend

BNY Mellon High Yield Strategies Fund Declares Dividend

NEW YORK–(BUSINESS WIRE)–
On April 26, 2023, the Board of Trustees of BNY Mellon High Yield Strategies Fund (NYSE: DHF) declared from net investment income a monthly cash dividend of $0.015 per share of beneficial interest, payable on May 24, 2023, to shareholders of record at the close of business on May 10, 2023. The ex-dividend date is May 9, 2023. The previous dividend declared in March was $0.015 per share of beneficial interest.

Important Information

BNY Mellon Investment Adviser, Inc., the investment adviser for the Fund, is part of BNY Mellon Investment Management. BNY Mellon Investment Management is one of the world’s largest asset managers, with $1.9 trillion in assets under management as of March 31, 2023. Through an investor-first approach, BNY Mellon Investment Management brings to clients the best of both worlds: specialist expertise from seven investment firms offering solutions across every major asset class, backed by the strength, stability, and global presence of BNY Mellon. Additional information on BNY Mellon Investment Management is available on www.bnymellonim.com.

BNY Mellon Investment Management is a division of BNY Mellon, which has $46.6 trillion in assets under custody and/or administration as of March 31, 2023. BNY Mellon can act as a single point of contact for clients looking to create, trade, hold, manage, service, distribute or restructure investments. BNY Mellon is the corporate brand of The Bank of New York Mellon Corporation (NYSE: BK). Additional information is available on www.bnymellon.com. Follow us on Twitter @BNYMellon or visit our newsroom at www.bnymellon.com/newsroom for the latest company news.

Closed-end funds are traded on the secondary market through one of the stock exchanges. The Fund’s investment returns and principal values will fluctuate so that an investor’s shares may be worth more or less than the original cost. Shares of closed-end funds may trade above (a premium) or below (a discount) the net asset value of the fund’s portfolio. There is no assurance that the Fund will achieve its investment objective.

This release is for informational purposes only and should not be considered as investment advice or a recommendation of any particular security.

For Press Inquiries:

BNY Mellon Investment Adviser, Inc.

Courtney Woolston

(212) 635-6027

For Other Inquiries:

BNY Mellon Securities Corporation

The National Marketing Desk

240 Greenwich Street

New York, New York 10286

1-800-334-6899

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Logo
Logo

Methanex Reports First Quarter 2023 Results

Except where otherwise noted, all currency amounts are stated in United States dollars.

  • Net income attributable to Methanex shareholders of $60 million and Adjusted EBITDA of $209 million in the first quarter. The average realized price in the first quarter was $371 per tonne compared to $373 per tonne in the fourth quarter of 2022.
  • Geismar 3 (“G3”) project is over 80% complete and is progressing safely, on time and on budget. Production expected in the fourth quarter of 2023. The remaining capital spend of $330 – 380 million is fully funded with cash on hand.
  • The Board approved a 6% dividend increase to $0.185 per share per quarter, applicable to the dividend payable on June 30th, 2023.
  • Returned $60 million to shareholders through dividends and share repurchases and have a strong liquidity position with $780 million in cash.

VANCOUVER, British Columbia, April 26, 2023 (GLOBE NEWSWIRE) — For the first quarter of 2023, Methanex (TSX:MX) (NASDAQ:MEOH) reported net income attributable to Methanex shareholders of $60 million ($0.87 net income per common share on a diluted basis) compared to net income of $41 million ($0.59 net income per common share on a diluted basis) in the fourth quarter of 2022. Net income was higher compared to the prior quarter primarily due to higher sales of Methanex-produced methanol driven by higher production in Egypt, Atlas and Chile. Adjusted EBITDA for the first quarter of 2023 was $209 million and Adjusted net income was $76 million ($1.11 Adjusted net income per common share). This compares with Adjusted EBITDA of $160 million and Adjusted net income of $51 million ($0.73 Adjusted net income per common share) for the fourth quarter of 2022.

In the first quarter methanol pricing remained relatively stable. The average realized price in the first quarter was $371 per tonne compared to $373 per tonne in the fourth quarter of 2022.

During the quarter, we returned $60 million to shareholders through the regular dividend and share repurchases. We ended the quarter with $780 million in cash, or approximately $709 million in cash excluding non-controlling interests and including our share of cash in the Atlas joint venture. We also have an undrawn $300 million revolving credit facility that provides additional financial flexibility.

Rich Sumner, President & CEO of Methanex, said, “I am proud of the team for delivering another quarter of strong operational and financial results. The G3 project is over 80% complete and we are looking forward to having it start up in the fourth quarter of this year as it will significantly enhance our cash flow generation capability and lower our average CO2 emissions intensity. Our business is well-positioned to navigate through the continuing macro-economic uncertainty and create shareholder value.”

FURTHER INFORMATION

The information set forth in this news release summarizes Methanex’s key financial and operational data for the first quarter of 2023. It is not a complete source of information for readers and is not in any way a substitute for reading the first quarter 2023 Management’s Discussion and Analysis (“MD&A”) dated April 26, 2023 and the unaudited condensed consolidated interim financial statements for the period ended March 31, 2023, both of which are available from the Investor Relations section of our website at www.methanex.com. The MD&A and the unaudited condensed consolidated interim financial statements for the period ended March 31, 2023 are also available on the Canadian Securities Administrators’ SEDAR website at www.sedar.com and on the United States Securities and Exchange Commission’s EDGAR website at www.sec.gov.

FINANCIAL AND OPERATIONAL DATA

  Three Months Ended
($ millions except per share amounts and where noted) Mar 31

2023
Dec 31
2022
Mar 31
2022
Production (thousands of tonnes) (attributable to Methanex shareholders) 1 1,660 1,526 1,789
Sales volume (thousands of tonnes)      
Methanex-produced methanol 1,649 1,360 1,797
Purchased methanol 848 1,095 682
Commission sales 308 192 279
Total sales volume 1 2,805 2,647 2,758
       
Methanex average non-discounted posted price ($ per tonne) 2 471 469 527
Average realized price ($ per tonne) 3 4 371 373 425
       
Revenue 1,038 986 1,176
Net income (attributable to Methanex shareholders) 60 41 119
Adjusted net income 4 76 51 159
Adjusted EBITDA 4 209 160 337
Cash flows from operating activities 162 227 326
       
Basic net income per common share 0.87 0.59 1.60
Diluted net income per common share 0.87 0.59 1.60
Adjusted net income per common share 4 1.11 0.73 2.16
       
Common share information (millions of shares)      
Weighted average number of common shares 69 70 74
Diluted weighted average number of common shares 69 70 74
Number of common shares outstanding, end of period 68 69 73

1 Methanex-produced methanol represents our equity share of volume produced at our facilities and excludes volume marketed on a commission basis related to the 36.9% of the Atlas facility and 50% of the Egypt facility that we do not own.
   
2 Methanex average non-discounted posted price represents the average of our non-discounted posted prices in North America, Europe, China and Asia Pacific weighted by sales volume. Current and historical pricing information is available at www.methanex.com.
   
3 The Company has used Average realized price (“ARP”) throughout this document. This is a non-GAAP ratio that does not have any standardized meaning prescribed by GAAP and therefore is unlikely to be comparable to similar measures presented by other companies. ARP is calculated as revenue, excluding commissions earned and the Egypt non-controlling interest share of revenue, but including an amount representing our share of Atlas revenue, divided by the total sales volume of Methanex-produced and purchased methanol. It is used by management to assess the realized price per unit of methanol sold, and is relevant in a cyclical commodity environment where revenue can fluctuate in response to market prices.
   
4 Note that Adjusted net income, Adjusted net income per common share, Adjusted EBITDA, and Average realized price are non-GAAP measures and ratios that do not have any standardized meaning prescribed by GAAP and therefore are unlikely to be comparable to similar measures presented by other companies. Refer to the Non-GAAP Measures section on page 12 of our first quarter MD&A dated April 26, 2023 for a description of each non-GAAP measure.
  • A reconciliation from net income attributable to Methanex shareholders to Adjusted EBITDA, Adjusted net income and the calculation of Adjusted net income per common share is as follows:
  Three Months Ended
($ millions)   Mar 31

2023
    Dec 31
2022
    Mar 31
2022
 
Net income attributable to Methanex shareholders $ 60   $ 41   $ 119  
Mark-to-market impact of share-based compensation   20     12     48  
Depreciation and amortization   98     86     92  
Finance costs   31     32     34  
Finance income and other expenses   (11 )   (18 )    
Income tax expense   14     7     42  
Earnings of associate adjustment   19     18     21  
Non-controlling interests adjustment   (22 )   (18 )   (19 )
Adjusted EBITDA attributable to Methanex shareholders $ 209   $ 160   $ 337  

  Three Months Ended
($ millions except number of shares and per share amounts)   Mar 31

2023
    Dec 31
2022
    Mar 31
2022
Net income attributable to Methanex shareholders $ 60   $ 41   $ 119
Mark-to-market impact of share-based compensation, net of tax   17     11     40
Impact of Egypt gas contract revaluation, net of tax   (1 )   (1 )  
Adjusted net income $ 76   $ 51   $ 159
Diluted weighted average shares outstanding (millions)   69     70     74
Adjusted net income per common share $ 1.11   $ 0.73   $ 2.16
  • We recorded net income attributable to Methanex shareholders of $60 million in the first quarter of 2023 compared to net income of $41 million in the fourth quarter of 2022. Net income was higher compared to the prior quarter primarily due to higher sales of Methanex-produced methanol driven by higher production in Egypt, Atlas and Chile.
  • We recorded Adjusted EBITDA of $209 million for the first quarter of 2023 compared to $160 million for the fourth quarter of 2022. We recorded Adjusted net income of $76 million for the first quarter of 2023 compared to Adjusted net income of $51 million for the fourth quarter of 2022. Adjusted EBITDA was higher in the first quarter of 2023 primarily due to higher sales of Methanex-produced methanol. The impact of higher Adjusted EBITDA on Adjusted net income for the first quarter of 2023, as compared to the fourth quarter of 2022, was partially offset by higher depreciation charges due to the mix of product sold and lower finance income due to lower foreign exchange gains.
  • We sold 2,805,000 tonnes in the first quarter of 2023 compared to 2,647,000 tonnes for the fourth quarter of 2022. Sales of Methanex-produced methanol were 1,649,000 tonnes in the first quarter of 2023 compared to 1,360,000 tonnes in the fourth quarter of 2022.
  • Production for the first quarter of 2023 was 1,660,000 tonnes compared to 1,526,000 tonnes for the fourth quarter of 2022. Production was higher for the first quarter of 2023 as production in the fourth quarter of 2022 was impacted by a planned extended turnaround in Egypt, seasonal gas restrictions in Chile and unplanned outages in Geismar and Trinidad.
  • The Geismar 3 project is progressing well and on budget with methanol production expected in the fourth quarter of 2023 with an expected total capital cost of $1.25 – 1.3 billion. The remaining cash expenditure of approximately $330 to $380 million, including approximately $75 million of spending accrued in accounts payable, is fully funded with cash on hand. Along with significantly enhancing our cash generation capability, Geismar 3 will have one of the lowest CO2 emissions intensity profiles in the industry, helping us meet our commitment to reduce our greenhouse gas emissions intensity.
  • To March 31, 2023, we have repurchased 1,923,432 common shares of 3,506,405 permitted under our current normal course issuer bid for $81 million, an average purchase price of approximately $42 per share. During the first quarter of 2023, we purchased 1,030,659 shares for $48 million.
  • In the first quarter of 2023 we paid a quarterly dividend of $0.175 per common share for a total of $12 million. On April 26, 2023 we announced a 6% increase in our quarterly dividend to $0.185 per common share. The increased dividend will apply to the dividend payable on June 30, 2023.
  • In March 2023, we released our 2022 Sustainability Report highlighting the progress on our Environmental, Social and Governance (ESG) commitments.
  • At March 31, 2023, we had a strong liquidity position including a cash balance of $780 million, or approximately $709 million excluding non-controlling interests and including our share of cash in the Atlas joint venture. We also have access to an undrawn $300 million revolving credit facility providing financial flexibility.

PRODUCTION HIGHLIGHTS

  Q1 2023 Q4 2022 Q1 2022
(thousands of tonnes) Operating Capacity

1
Production Production Production
USA (Geismar) 550 449 437 556
New Zealand 2 550 403 395 386
Trinidad (Methanex interest) 3 490 256 225 258
Chile 425 249 226 324
Egypt (50% interest) 158 161 96 104
Canada (Medicine Hat) 160 142 147 161
  2,333 1,660 1,526 1,789

1 The operating capacity of our production facilities may be higher or lower than original nameplate capacity as, over time, these figures have been adjusted to reflect ongoing operating efficiencies at these facilities. Actual production for a facility in any given year may be higher or lower than operating capacity due to a number of factors, including natural gas availability, feedstock composition, the age of the facility’s catalyst, turnarounds and access to CO2 from external suppliers for certain facilities. We review and update the operating capacity of our production facilities on a regular basis based on historical performance. 
   
2 The operating capacity of New Zealand is made up of the two Motunui facilities and the Waitara Valley facility. The Waitara Valley plant is idled indefinitely due to natural gas constraints.
   
3 The operating capacity of Trinidad is made up of the Titan (100% interest) and Atlas (63.1% interest) facilities. The Titan plant is idled indefinitely due to natural gas constraints.

Key production and operational highlights during the first quarter and production outlook for 2023 include:

United States

Geismar produced 449,000 tonnes in the first quarter compared to 437,000 tonnes in the fourth quarter of 2022. A planned turnaround was completed at Geismar 1 in the first quarter and the plant successfully restarted in late February. Production was higher in the first quarter as the fourth quarter was impacted by an unplanned outage in October caused by a utilities supplier that experienced a loss of power due to a failed transformer.

New Zealand

New Zealand produced 403,000 tonnes in the first quarter of 2023 compared to 395,000 tonnes in the fourth quarter of 2022. We estimate production for 2023 to be between 1.3 – 1.4 million tonnes.

Trinidad

Atlas produced 256,000 tonnes (Methanex interest) in the first quarter of 2023 compared to 225,000 tonnes in the fourth quarter of 2022. Production was higher in the first quarter as the fourth quarter was impacted by an unplanned outage. Titan remains idled indefinitely.

Chile

Chile produced 249,000 tonnes in the first quarter of 2023 compared to 226,000 tonnes in the fourth quarter of 2022. Production was higher in the first quarter due to higher gas deliveries from Argentina. We estimate Chile production in 2023 to be between 0.8 – 0.9 million tonnes.

Egypt

Egypt produced 322,000 tonnes (Methanex interest – 161,000 tonnes) in the first quarter of 2023 compared to 192,000 tonnes (Methanex interest – 96,000 tonnes) in the fourth quarter of 2022. Production was higher in the first quarter as the fourth quarter was impacted by a planned turnaround.

Canada

Medicine Hat produced 142,000 tonnes in the first quarter of 2023 compared to 147,000 tonnes in the fourth quarter of 2022.

2023 Production Outlook

Forecasted production for 2023 is approximately 6.5 million equity tonnes, excluding any production from G3. Actual production may vary by quarter based on timing of turnarounds, gas availability, unplanned outages and unanticipated events.

CONFERENCE CALL

A conference call is scheduled for April 27, 2023 at 11:00 am ET (8:00 am PT) to review these first quarter results. To access the call, dial the conferencing operator fifteen minutes prior to the start of the call at (646) 960-0479, or toll free at (888) 510-2296. The conference ID for the call is #7014770. A simultaneous audio-only webcast of the conference call can be accessed from our website at www.methanex.com/investor-relations/events and will also be available following the call.

ABOUT METHANEX

Methanex is a Vancouver-based, publicly traded company and is the world’s largest producer and supplier of methanol to major international markets. Methanex shares are listed for trading on the Toronto Stock Exchange in Canada under the trading symbol “MX” and on the NASDAQ Global Market in the United States under the trading symbol “MEOH”.

FORWARD-LOOKING INFORMATION WARNING

This first quarter 2023 press release contains forward-looking statements with respect to us and the chemical industry. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond the Company’s control. Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Methanex does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law. Refer to Forward-Looking Information Warning in the first quarter 2023 Management’s Discussion and Analysis for more information which is available from the Investor Relations section of our website at www.methanex.com, the Canadian Securities Administrators’ SEDAR website at www.sedar.com and on the United States Securities and Exchange Commission’s EDGAR website at www.sec.gov.

NON-GAAP MEASURES

The Company has used the terms Adjusted EBITDA, Adjusted net income, Adjusted net income per common share and Average realized price throughout this document. These items are non-GAAP measures and ratios that do not have any standardized meaning prescribed by GAAP. These measures represent the amounts that are attributable to Methanex Corporation shareholders and are calculated by excluding the mark-to-market impact of share-based compensation as a result of changes in our share price, the impact of the Egypt gas contract revaluation and the impact of certain items associated with specific identified events. Refer to Additional Information – Non-GAAP Measures on page 12 of the Company’s MD&A for the period ended March 31, 2023 for reconciliations to the most comparable GAAP measures. Unless otherwise indicated, the financial information presented in this release is prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”).

For further information, contact:

Sarah Herriott
Director, Investor Relations
Methanex Corporation
604-661-2600



FCPT Announces Acquisition of an Arby’s Property for $1.2 Million

FCPT Announces Acquisition of an Arby’s Property for $1.2 Million

MILL VALLEY, Calif.–(BUSINESS WIRE)–
Four Corners Property Trust (NYSE:FCPT), a real estate investment trust primarily engaged in the ownership and acquisition of high-quality, net-leased restaurant and retail properties (“FCPT” or the “Company”), is pleased to announce the acquisition of an Arby’s property for $1.2 million. The property is located in a highly trafficked corridor in Kentucky and is corporate-operated under a triple net lease with approximately five years of term remaining. The transaction was priced at a 6.7% cap rate, exclusive of transaction costs.

About FCPT

FCPT, headquartered in Mill Valley, CA, is a real estate investment trust primarily engaged in the ownership, acquisition and leasing of restaurant and retail properties. The Company seeks to grow its portfolio by acquiring additional real estate to lease, on a net basis, for use in the restaurant and retail industries. Additional information about FCPT can be found on the website at www.fcpt.com.

Four Corners Property Trust:

Bill Lenehan, 415-965-8031

CEO

Gerry Morgan, 415-965-8032

CFO

KEYWORDS: California Kentucky United States North America

INDUSTRY KEYWORDS: REIT Restaurant/Bar Retail Commercial Building & Real Estate Construction & Property

MEDIA: